All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-000081-13 | A randomized, controlled, open-label, multi-center, parallel group study to demonstrate efficacy and safety of RO0503821 when administered with pre-filled syringes for the maintenance treatment of ane... | 2006-01-10 | due-trials |
| Reported results | 2004-000231-29 | Safety and pharmacokinetics of valganciclovir syrup formulation in paediatric solid organ transplant recipients | 2005-05-15 | due-trials |
| Reported results | 2004-000282-35 | A randomised, double-blind phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (Roferon) versus interferon alfa-2a and placebo as first line treat... | 2011-06-27 | due-trials |
| Reported results | 2004-000315-26 | First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. Estudio abierto, no comparativo, multicéntrico de bevacizumab más quimioterapia en el tratamiento de primera lín... | 2007-10-01 | due-trials |
| Reported results | 2004-000564-28 | AN EXPANDED ACCESS PROGRAM OF TARCEVA (ERLOTINIB) IN PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER | 2009-04-17 | due-trials |
| Reported results | 2004-000596-34 | A prospective, randomized, double-blind, placebo controlled, parallel group, multicenter, 36-weeks trial to assess the efficacy and safety of adjunct mycophenolate mofetil (MMF) to maintain or improve... | 2006-09-04 | due-trials |
| Reported results | 2004-000715-26 | A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/ Leuco... | 2012-11-30 | due-trials |
| Reported results | 2004-000752-17 | Phase II study of Herceptin, alone or in combination with a taxane, as a first-line treatment for patients with metastatic breast cancer, who have relapsed after receiving Herceptin in the djuvant set... | 2012-06-21 | due-trials |
| Reported results | 2004-000864-29 | A randomized, double-blind multicenter 2-stage phase III study of bevacizumab in combination with cisplatin and gemcitabine versus placebo, cisplatin and gemcitabine in patients with advanced or recur... | 2016-06-30 | due-trials |
| Reported results | 2004-000983-29 | Effectiveness of a once weekly subcutaneous sc epoetin beta treatment in hemodialysis patients. | 2006-11-27 | due-trials |
| Reported results | 2004-001224-21 | A 24 week, open label single arm study to evaluate the safety and efficacy of switching a toxicity causing antiretroviral ARV to enfuvirtide ENF and to assess resolution or improvement of ARV toxic... | 2006-10-23 | due-trials |
| Reported results | 2004-001298-24 | An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using intravenous injections of RO0503821 in patients with chronic kidney disease who are on dialysis | 2005-12-08 | due-trials |
| Reported results | 2004-001548-60 | Double-blind, partially randomized, parallel group, multicenter study to assess the efficacy and safety of 100 mg and 150 mg monthly oral ibandronate in women with postmenopausal osteoporosis having c... | 2008-05-20 | due-trials |
| Ongoing | 2004-001685-40 | An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination with Intravenous Oxaliplatin (Q3W) (“XELOX”) versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leu... | not-yet-due | |
| Reported results | 2004-001688-23 | A multicentre, double-blind, placebo-controlled randomized trial of the efficacy, safety and tolerability of 12 months of once daily treatment with 1 mg of RO3300074 in patients with symptomatic emphy... | 2008-05-27 | due-trials |
| Reported results | 2004-001718-15 | An open-label, multicenter protocol providing pegylated interferon alfa 2-a PEGASYS as monotherapy or in combination with ribavirin COPEGUS for patients with chronic hepatitis C who have partecipat... | 2011-09-26 | due-trials |
| Reported results | 2004-001854-10 | Randomized, two arm, placebo controlled double dummy study to compare the efficacy of intravenous loading doses followed by maintenance treatment with oral ibandronic acid versus zoledronic acid in pa... | 2007-02-06 | due-trials |
| Reported results | 2004-001855-12 | Randomized, two arm, placebo controlled study to compare the efficacy of IV loading doses followed by maintenance treatment with IV ibandronic acid versus zoledronic acid in patients with skeletal met... | 2007-02-06 | due-trials |
| Reported results | 2004-002032-26 | An open-label, multi-center study to document the efficacy, safety and tolerability of long-term administration of RO0503821 in patients with chronic renal anemia | 2010-01-22 | due-trials |
| Reported results | 2004-002093-30 | Extension protocol for patients with Chronic Myelogenous Leukemia (CML), Malignant Melanoma (MM) or Renal Cell Carcinoma (RCC) that have responded to treatment with Pegylated-interferon α-2a (PEG-IFN)... | 2008-01-01 | due-trials |
| Reported results | 2004-002131-12 | Evaluation of efficacy and safety of ibandronate as treatment of metastatic bone pain in patients with different tumor types. A randomised phase II study | 2007-03-29 | due-trials |
| Exempt, with results | 2004-002132-26 | A randomized placebo-controlled, multicenter, blinded Phase I/II study of the safety of escalating single intravenous doses of ocrelizumab (Ro 496-4913, PRO70769, rhuMAb 2H7) in patients with moderate... | 2013-02-06 | not-yet-due |
| Reported results | 2004-002255-14 | Randomized, double-blind, double-dummy, parallel group, multicenter study to compare the efficacy and safety of once-monthly oral administration of 150 mg ibandronate with once-weekly oral administrat... | 2007-06-17 | due-trials |
| Reported results | 2004-002570-32 | Open label, parallel group, multicenter study of two IV ibandronate dose regimens (2 mg every 2 months and 3 mg every 3 months) in women with postmenopausal osteoporosis who completed trial BM 16550. | 2010-11-27 | due-trials |
| Completed, but no date, and reported results | 2004-002733-39 | FC + rituximab followed by rituximab maintenance treatment in patients with advanced untreated Indolent B-cell Non follicular Lymphomas: phase II study. FC + rituximab seguito da terapia di manteni... | bad-data | |
| Listed as ongoing, but also has a completion date | 2004-002787-15 | Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FC-R) versus chemotherapy with Fludarabine and Cyclophosophamide (FC) alone in patients with previously... | 2011-12-12 | bad-data |
| Reported results | 2004-002798-21 | A Phase II, prospective, randomized, double-blind, active-controlled, parallel group, multi-center 'proof of concept' trial in adult patients with community-acquired pneumonia requiring hospitalizatio... | 2006-08-24 | due-trials |
| Reported results | 2004-002854-78 | A randomised, double blind, placebo controlled, multicentre phase III trial to evaluate the efficacy and safety of adding bevacizumab to gemcitabine and erlotinib in patients with metastatic pancreati... | 2008-03-26 | due-trials |
| Completed, but no date, and reported results | 2004-002985-39 | A multicenter, randomized, controlled study comparing the efficacy and safety of 48 weeks of 40kD branched pegylated interferon alfa-2a (PEGASYS, Ro 25-8310) versus 96 weeks of PEGASYS, alone or in co... | bad-data | |
| Reported results | 2004-003733-14 | A randomized, double-blind, parallel group study of the safety and prevention of structural joint damage during treatment with MRA versus placebo, in combination with methotrexate, in patients with mo... | 2012-02-25 | due-trials |
| Reported results | 2004-003741-40 | A randomized, double-blind, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with methotrexate, in patients with moderate... | 2007-01-10 | due-trials |
| Reported results | 2004-004021-98 | A single arm Phase IV study to assess efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-fluorouracil/folinic acid regimens as first line treatment for patients with me... | 2007-10-10 | due-trials |
| Ongoing | 2004-004022-27 | Phase IIa, multicenter, randomised, double-blind, placebo controlled study of the efficacy and safety of RO0506997, an α4 integrin antagonist, in combination with methotrexate, versus methotrexate alo... | not-yet-due | |
| Exempt, with results | 2004-004110-17 | Full title of the trial : An open-label, multicentre, dose-escalating phase I/II trial of 3-weekly rhuMAb 2H7 in patients with follicular non Hodgkin’s lymphoma | 2008-01-21 | not-yet-due |
| Reported results | 2004-004358-24 | A phase IIIb/IV randomised, controlled study evaluating an intensification treatment strategy of adding enfuvirtide (ENF) to an oral Highly Active AntiRetroviral Therapy (HAART) in treatment experienc... | 2008-04-28 | due-trials |
| Ongoing | 2004-004519-43 | Estudio de Fase 2, Multicéntrico, Aleatorizado, Doble Ciego, Controlado con Placebo, de Grupos Paralelos y de Escalada de Dosis para determinar el Efecto del RO0506997 sobre las lesiones en Imagen de ... | not-yet-due | |
| Completed, but no date, and reported results | 2004-004528-11 | Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPPIV inhibitor RO0730699 in patients wi... | bad-data | |
| Reported results | 2004-004529-84 | Multicenter, double-blind, randomized, placebo controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPP-IV inhibitor RO0730699 in patients w... | 2006-06-19 | due-trials |
| Reported results | 2004-004852-38 | A randomized, open label, multicenter, parallel group study evaluating the efficacy and safety of 135 mcg and 90 mcg of Pegasys given as monotherapy to patients with chronic hepatitis C and end-stage ... | 2008-12-17 | due-trials |
| Reported results | 2004-005096-42 | A phase II marker identification trial for Tarceva in second line NSCLC patients | 2009-06-09 | due-trials |
| Reported results | 2004-005210-37 | A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD t... | 2007-05-02 | due-trials |
| Reported results | 2005-000285-39 | Randomized Phase II Trial Testing the Efficacy of Three Bevacizumab-Containing First-Line Regimens for Metastatic Colorectal Cancer. Studio multicentrico, randomizzato di fase II, di valutazione de... | 2012-11-02 | due-trials |
| Completed, but no date, and reported results | 2005-000336-25 | Longitudinal analysis of HBV-specific T cell responses in patients with HBeAg-negative chronic hepatitis B (CHB) treated with pegylated interferon alfa-2a (40 KD) (PEGASYS, Ro 25-8310). Immunolog... | bad-data | |
| Reported results | 2005-000343-28 | An optional continuation of double-blind treatment for subjects who have achieved good symptom control with stable prednisone dosing and who have completed Protocol WX17798 A prospective, randomized,... | 2006-11-26 | due-trials |
| Reported results | 2005-000359-13 | Hungarian Study of Maintenance after Rituximab Pretreatment. A multicentre, phase III, open-label study evaluating the benefit of a long-term MabThera® (rituximab) maintenance therapy in patients with... | 2013-08-12 | due-trials |
| Reported results | 2005-000387-39 | An open-label randomized multicentre phase III study of trastuzumab in combination with a fluoropyrimidine and cisplatin versus chemotherapy alone as first-line therapy in patients with HER2 positive ... | 2010-07-07 | due-trials |
| Reported results | 2005-000535-18 | Prospective, multicenter study to evaluate the renal safety of 6 mg ibandronic acid infusions over 15 min or 60 min in patients with metastatic bone disease due to breast cancer. | 2006-05-31 | due-trials |
| Reported results | 2005-000557-30 | A phase II, open- label, controlled, randomized, multicenter study to evaluate the efficacy and safety of pertuzumab (Omnitarg™), a recombinant humanized antibody against HER2, in combination with ca... | 2011-03-04 | due-trials |
| Reported results | 2005-000669-21 | Pilot study of HIV Viral slope in naive patients treated with Enfuvirtide (ENF) based therapy compared to current standard treatment. | 2008-08-28 | due-trials |
| Completed, but no date, and reported results | 2005-000802-30 | Phase II study of the combination of Bevacizumab (rhuMab VEGF) plus Capecitabine with pre-operative standard radiotherapy in patients with locally advanced rectal cancer. Studio di fase II sulla co... | bad-data | |
| Completed, but no date, and reported results | 2005-000859-15 | Randomized prospective study comparing dexamethasone and dexamethasone plus rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP) in adults. | bad-data | |
| Reported results | 2005-000884-25 | A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with methotrexate in pat... | 2007-04-23 | due-trials |
| Completed, but no date, and reported results | 2005-001012-41 | Phase II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Oxaliplatin plus Capecitabine (XELOX) in Patients with Advanced Colorectal Cancer Studio di fase II sulla combinazione di bevacizu... | bad-data | |
| Reported results | 2005-001138-33 | A randomized, double-blind, double-dummy, parallel group study of the safety and efficacy of MRA monotherapy, versus methotrexate MTX monotherapy, in patients with active rheumatoid arthritis. | 2007-12-19 | due-trials |
| Reported results | 2005-001183-31 | A prospective, open label, randomized, multicenter, multinational study evaluating the overall efficacy and safety including the effect on renal function of sirolimus (Rapamune) replacing CNI in a sta... | 2006-06-01 | due-trials |
| Completed, but no date, and reported results | 2005-001220-37 | A pilot study of trastuzumab monotherapy in patients who progressed under a previous platinum-based or 5-fluoropyrimidin-based chemotherapy in metastatic or locally advanced gastric cancer | bad-data | |
| Reported results | 2005-001502-11 | “CHAIROS” – Early brief intensification by chemoimmunotherapy with FCR followed by FR and Rituximab maintenance in chemonaive patients with B-CLL – A phase II study | 2012-09-24 | due-trials |
| Reported results | 2005-002239-29 | A phase II prospective, open label, randomized, active-controlled, parallel group, multi-center ‘proof of concept’ trial in adult patients with complicated skin and skin structure infections requiring... | 2007-02-16 | due-trials |
| Reported results | 2005-002241-39 | A multicentre, double blind randomised, phase III study to evaluate the efficacy of Tarceva or placebo following 4 cycles of platinum-based chemotherapy in patients with histologically documented, adv... | 2011-11-09 | due-trials |
| Completed, but no date, and reported results | 2005-002385-11 | - STUDIO MULTICENTRICO DI FASE III IN APERTO RANDOMIZZATO A TRE BRACCI DI CONFRONTO TRA 1 ANNO E 2 ANNI DI TRATTAMENTO CON HERCEPTIN VERSO NESSUN TRATTAMENTO CON HERCEPTIN IN DONNE AFFETTE DA TUMOR... | bad-data | |
| Reported results | 2005-002392-32 | A randomised, placebo controlled, double-blind, parallel group, international study to evaluate the safety and efficacy of rituximab (MabThera/Rituxan) in combination with methotrexate, compared to me... | 2013-07-23 | due-trials |
| Reported results | 2005-002395-15 | A randomized, phase 3, controlled, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of rituximab in combination with methotrexate (MTX) compared to MTX alone, in met... | 2013-07-22 | due-trials |
| Reported results | 2005-002396-33 | A randomised, double-blind, international study to evaluate the efficacy and safety of various re-treatment regimens of rituximab in combination with methotrexate in RA patients with an inadequate ... | 2013-03-25 | due-trials |
| Reported results | 2005-002423-13 | Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in WA 17822 Studio di estensione sulla sicurezza a lungo termine del trattamento con MR... | 2012-05-02 | due-trials |
| Completed, but no date Terminated | 2005-002802-48 | Evaluation of efficacy and safety of i.v. and oral ibandronate in elderly patients with bone metastases from solid tumors. A randomised phase II study | bad-data | |
| Reported results | 2005-002817-19 | A Randomized, Double-Blind, Placebo Controlled Multi-Center Study of the Efficacy and Safety of up to 100 days of Valganciclovir vs. up to 200 days of Valganciclovir for Prevention of Cytomegalovirus... | 2009-08-13 | due-trials |
| Completed, but no date, and reported results | 2005-002818-38 | ESPrES 500 - Evaluation of the safety profile of the new 500 mg film-coated tablet (FCT) formulation of boosted saquinavir (Invirase 500 mg) in HIV-1 infected patients | bad-data | |
| Reported results | 2005-002907-18 | A multi-center phase 2 randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of RO4389620 in patients with type 2 diabete... | 2007-01-17 | due-trials |
| Reported results | 2005-002908-42 | A multi-center, double-blind, randomized, placebo-controlled dose-ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of RO4389620 in patients with type 2 diabetes... | 2006-11-09 | due-trials |
| Reported results | 2005-002909-23 | Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies. | 2013-04-24 | due-trials |
| Reported results | 2005-002910-39 | A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 over a 24-week period in Patients with CHD or a CHD Risk Equivalent | 2007-08-28 | due-trials |
| Reported results | 2005-003220-19 | A multicentre, open-label, randomized, phase III study to evaluate the efficacy of Tarceva or comparator Alimta (pemetrexed) or Taxotere (docetaxel) in patients with histologically documented, advance... | 2012-06-22 | due-trials |
| Reported results | 2005-003264-38 | COMPARE: Comparison Ibandronate - Zoledronate regarding nephrotoxicity in patients with multiple myeloma | 2009-04-03 | due-trials |
| Reported results | 2005-003383-39 | A randomized, open-label, multi-center study comparing a steroid sparing regimen versus standard steroid regimen in combination with daclizumab, mycophenolate mofetil and sirolimus in the prevention o... | 2006-07-11 | due-trials |
| Completed, but no date, and reported results | 2005-003416-30 | Phase II study of Dacarbazine with the anti-vascular endothelial growth factor antibody (Bevacizumab) in patients with unresectable/metastatic melanoma. Studio di fase II sull`associazione di Daca... | bad-data | |
| Reported results | 2005-003493-19 | An exploratory phase II, single arm, multicenter study to evaluate the efficacy and safety of the combination of pertuzumab and Herceptin (trastuzumab) in patients with HER2-positive metastatic breast... | 2015-09-01 | due-trials |
| Reported results | 2005-003495-38 | A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (MTX)... | 2007-11-23 | due-trials |
| Reported results | 2005-003632-22 | An open-label, exploratory study of the pharmacokinetic and pharmacodynamic activity of rituximab in combination with methotrexate (MTX) in synovial tissue and in peripheral blood of patients with act... | 2012-05-10 | due-trials |
| Reported results | 2005-003694-25 | A randomized, double-blind, double-dummy, parallel group study to determine the efficacy and safety of RO4402257 monotherapy in comparison to methotrexate monotherapy in patients with active rheumatoi... | 2007-06-21 | due-trials |
| Reported results | 2005-003770-23 | Comparative Trial inMultiple Myeloma Patients of Oral Ibandronic Acid versus Intravenous Zoledronate: a phase III study | 2006-05-31 | due-trials |
| Reported results | 2005-003862-40 | A randomised, double blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of bevacizumab in combination with docetaxel compared with docetaxel plus placebo, as first line ... | 2013-10-24 | due-trials |
| Completed, but no date, and reported results | 2005-003932-23 | An Open-Label, Multicenter Phase IV Study assessing safety and efficacy of ribavirin (Copegus®) as part of combination therapy with peginterferon alfa-2a (Pegasys®) in selected groups of patients with... | bad-data | |
| Completed, but no date, and reported results | 2005-004189-17 | An open-label, single arm, multicenter study to assess the safety and efficacy of once-weekly administration of NeoRecormon using the 30.000 IU prefilled syringe in anaemic adult patients with solid t... | bad-data | |
| Completed, but no date, and reported results | 2005-004216-70 | A randomized, double-blind, parallel group, placebo-controlled with open-label active comparator arm , dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of RO07... | bad-data | |
| Reported results Terminated | 2005-004268-21 | A multicenter, open label, extension study to evaluate the long-term safety and tolerability of RO4389620 in type 2 diabetic patients from studies BM18248 or BM18249. | 2007-07-02 | due-trials |
| Reported results | 2005-004510-33 | A randomized, controlled, open-label, multi-center, parallel-group study to compare the efficacy and safety of RO0503821 with that of darbepoetin alfa administered intravenously at extended dosing int... | 2008-11-27 | due-trials |
| Reported results | 2005-004605-29 | A Phase IIIb Study of Tarceva (Erlotinib) in patients with locally advanced, unresectable or metastatic pancreatic cancer Studio Clinico di Fase IIIb in pazienti con carcinoma del pancreas ad uno ... | 2011-04-27 | due-trials |
| Exempt, with results | 2005-004662-16 | Estudio fase I/II de la adición de erlotinib a la combinación de bevacizumab, capecitabina y oxaliplatino a dosis fijas, como terapia de primera línea en pacientes con adenocarcinoma colorrectal metas... | not-yet-due | |
| Reported results | 2005-004695-20 | Randomized multicenter trial comparing Valganciclovir CMV prophylaxis versus pre-emptive therapy after renal transplantation using proteomics for monitoring of graft alteration | 2015-10-26 | due-trials |
| Ongoing | 2005-004760-23 | “Estudio abierto, aleatorizado y comparativo, para establecer la seguridad y eficacia de Bondronat i.v. (6 mg) en pacientes con cáncer de mama y metástasis óseas, que presentan dolor de moderado a gra... | not-yet-due | |
| Reported results | 2005-004782-41 | A parallel phase II study of Tarceva (Erlotinib) in patients with advanced non-small cell lung cancer (Stage IIIB/IV) non pre-treated by chemotherapy including dose escalation to toxicity in current a... | 2009-11-10 | due-trials |
| Completed, but no date | 2005-004976-18 | An Open-Label Randomized Phase II Study of Two Different Dosing Regimens of Capecitabine in Combination with Intravenous Docetaxel (Q3W) in Patients with Locally Advanced and/or Metastatic Breast Ca... | bad-data | |
| Reported results | 2005-004977-12 | A Phase IIIb study of MabThera rituximab maintenance therapy in patients with follicular Non-Hodgkin s Lymphoma who have responded to induction therapy. | 2011-12-19 | due-trials |
| Reported results | 2005-005399-34 | A randomised, open-label, multi-national study to investigate the impact of bone marker feedback (at 2 months) on adherence to once monthly Ibandronate treatment for post-menopausal osteoporosis (PMO) | 2007-11-13 | due-trials |
| Reported results | 2005-005405-37 | A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV nonsmall cell lung cancer receiving first line myelosuppressive chemotherapy | 2017-04-13 | due-trials |
| Reported results | 2005-005506-23 | A Randomized, Multicenter, Double Blinded, Phase IV Study Comparing the Safety and Efficacy of Pegasys 180 µg plus Copegus 1000 or 1200 mg to the Currently Approved Combination of Pegasys 180 µg plus ... | 2009-04-30 | due-trials |
| Reported results | 2005-005507-41 | Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Hig... | 2009-04-22 | due-trials |
| Reported results | 2005-005529-74 | A randomised, open-label, multi-national, multi-center study to investigate the impact of bone-marker feedback (at 3 months) on adherence to once monthly ibandronate treatment of patients with post-me... | 2008-01-22 | due-trials |
| Reported results | 2005-005533-35 | An open-label, non-controlled study of bevacizumab in combination with cisplatin-gembitabine or carboplatin-paclitaxel, as first line treatment for patients with advanced or recurrent squamous non-sma... | 2007-07-16 | due-trials |
| Reported results | 2005-005883-10 | A phase II study of Bevacizumab with Docetaxel and Capecitabine in the neoadjuvant setting for breast cancer patients | 2007-09-25 | due-trials |
| Reported results | 2005-005887-97 | Estudio abierto sobre bevacizumab(AVASTIN®) en combinación con quimioterapia basada en platino como tratamiento de primera línea de pacientes con carcinoma de pulmón no microcítico, no epidermoide, av... | 2009-11-09 | due-trials |
| Reported results | 2005-006161-13 | A single arm Phase II study to assess efficacy and safety of bevacizumab in combination with the standard therapy (interferon alfa-2a and vinblastine) as first-line treatment for patients with metasta... | 2010-01-21 | due-trials |
| Reported results | 2005-006162-33 | Relationships between pharmacokinetic and pharmacodynamic strategies for assessment of the risks for acute rejection and side effects of mofetil mycophenolate | 2008-09-09 | due-trials |
| Completed, but no date, and reported results | 2006-000011-15 | A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of once monthly inbandronate in the prevention of glucocorticoid-induced osteoporosis in postmenopausal wome... | bad-data | |
| Reported results Terminated | 2006-000026-31 | Bevacizumab as treatment for patients with relapsed/refractory multiple myeloma | 2008-07-31 | due-trials |
| Completed, but no date Terminated | 2006-000137-35 | Prospective controlled clinical trial of metastatic breast cancer treatment with capecitabine/docetaxel in combination with beta epoetin as compared with sole capecitabine/docetaxel treatment | bad-data | |
| Reported results | 2006-000254-51 | A phase 2, multicenter, open label, titration study to assess the efficacy, safety and tolerability of RO4389620 in doses up to 200 mg BID in patients with type 2 diabetes mellitus not optimally contr... | 2007-04-26 | due-trials |
| Ongoing | 2006-000608-18 | Estudio abierto y aleatorizado, comparativo de la tolerabilidad renal de Bondronat® 6 mg I.V. en perfusión de 15 minutos frente a 60 minutos en pacientes con metástasis óseas | not-yet-due | |
| Completed, but no date, and reported results Terminated | 2006-000703-42 | A phase III randomized trial of trastuzumab continuation vs discontinuation in combination with 2nd-line chemotherapy after progression on a 1st-line trastuzumab-chemotherapy combination for HER2 ove... | bad-data | |
| Reported results | 2006-000870-63 | A phase IV, 2x2 factorial, double blind study of 24 versus 48 weeks and 90 versus 180 mcg doses of pegylated interferon alfa 2a 40KD (PEG IFN, Ro 25-8310) in adult patients with HBeAg positive chronic... | 2010-06-30 | due-trials |
| Reported results | 2006-000935-86 | Randomized, multicentric, partially double blind placebo-controlled phase II study for examining the influence of Ribavirin on the initial virological response in previous untreated patients with chro... | 2010-05-24 | due-trials |
| Reported results Terminated | 2006-000961-12 | Prospective study to investigate if patients on reduced-dose EC-MPS treatment due to gastrointestinal problems can be switched to a higher than the equimolar dose of MMF | 2007-10-31 | due-trials |
| Reported results | 2006-000977-31 | PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC HE... | 2020-01-29 | due-trials |
| Reported results | 2006-001000-37 | Efficacy and safety of rituximab in patients with rheumatoid arthritis | 2010-11-18 | due-trials |
| Completed, but no date Terminated | 2006-001011-29 | A phase II study to assess the efficacy of intravenous loading doses of Bondronat 6 mg on metastatic bone pain in patients with breast cancer and skeletal metastases | bad-data | |
| Reported results | 2006-001365-42 | A randomized, open-label, 2-arm, multicentre, phase III study to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab / docetaxel compared with trastuzumab / docetaxel alone... | 2015-01-08 | due-trials |
| Reported results | 2006-001434-41 | An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using once monthly subcutaneous injections of RO0503821 in patients with chronic kidney disease who a... | 2009-10-07 | due-trials |
| Completed, but no date, and reported results | 2006-001517-15 | Italian multicenter phase II trial using Fotemustine plus Bevacizumab as first-line therapy in metastatic melanoma. | bad-data | |
| Reported results | 2006-001518-34 | Estudio fase II abierto, no aleatorizado, de erlotinib en combinación con gemcitabina en pacientes con adenocarcinoma de páncreas avanzado irresecable o metastásico: relación entre rash cutáneo y sup... | 2010-03-23 | due-trials |
| Reported results | 2006-001682-42 | Rituximab phase IIIb open-label, multi-centre assessment of safety and effectiveness in patients with RA following inadequate response to one prior anti-TNF inhibitor (RESET). | 2009-05-01 | due-trials |
| Reported results | 2006-001845-33 | Estudio fase III randomizado, controlado de erlotinib (Tarceva®) como tratamiento de mantenimiento en pacientes con carcinoma epidermoide de cabeza y cuello resecado y tratado con radioterapia con o ... | 2009-12-18 | due-trials |
| Reported results | 2006-002119-28 | Open label, randomized, multicenter study to investigate the efficacy and safety of once-weekly (reduced administration frequency) NeoRecormon® (Epoetin beta) therapy versus thrice weekly NeoRecormon®... | 2006-11-21 | due-trials |
| Reported results | 2006-002180-72 | Open Label Study to Establish the Short Term Efficacy of Intravenous Loading-Doses of Bondronat 6mg in Patients with Breast Cancer and Skeletal Metastases Experiencing Moderate to Severe Pain, within ... | 2009-01-12 | due-trials |
| Reported results | 2006-002468-24 | A double-blind, randomized, stratified, multi-center trial evaluating conventional and double dose oseltamivir in the treatment of immunocompromised patients with influenza | 2017-05-02 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2006-002473-47 | A double blind, randomized, placebo controlled, multi-center trial of oseltamivir for the seasonal prophylaxis of influenza in immunocompromised patients. | 2008-06-03 | bad-data |
| Reported results | 2006-002525-23 | A double-blind, placebo-controlled efficacy as assessed by post-bronchodilatator FEV1 and safety study of 5 mg RO3300074 once-daily for 2 years in subjects with smoking-related, moderate to severe C... | 2010-05-25 | due-trials |
| Reported results | 2006-002529-21 | Estudio abierto de Bevacizumab (Avastin®) más Taxanos en monoterapia o en combinación, en primera linea de tratamiento de pacientes con cáncer de mama metastásico o locallmente recurrente(CMM o LR). ... | 2013-06-25 | due-trials |
| Reported results | 2006-002860-25 | A multicenter randomized phase II trial to compare trastuzumab (Herceptin®) continuation or discontinuation in combination with 2nd-line chemotherapies after progression on a 1st-line chemotherapy com... | 2011-08-27 | due-trials |
| Reported results | 2006-003284-31 | An open label multi-center trial of oseltamivir for the seasonal prophylaxis of influenza in children | 2007-05-23 | due-trials |
| Completed, but no date, and reported results | 2006-003291-35 | Phase II, open label, neoadjuvant study of Bevacizumab in patients with inflammatory or locally advanced breast cancer | bad-data | |
| Reported results | 2006-003293-10 | A randomised, open-label Phase III study to assess efficacy and safety of bevacizumab in combination with capecitabine as first line treatment for elderly patients with metastatic colorectal cancer | 2013-03-08 | due-trials |
| Completed, but no date, and reported results | 2006-003441-16 | OPEN LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS LOADING DOSE OF 3X 6MG IBANDRONIC ACID (BONDRONAT®) DURING 3 CONSECUTIVE DAYS IN PATIENTS WITH BREAST CANCER AND SKELETAL METASTASES... | bad-data | |
| Reported results | 2006-003472-35 | Essai randomisé de phase II évaluant l’efficacité et la tolérance de deux stratégies néoadjuvantes avec bevacizumab, visant à optimiser le traitement de patients atteints d’un cancer rectal localement... | 2016-03-23 | due-trials |
| Ongoing | 2006-003821-10 | Estudio aleatorizado, abierto y cruzado para evaluar la tolerabilidad del dispositivo de inyección sin aguja B2000 para la administración de enfuvirtida. | not-yet-due | |
| Completed, but no date, and reported results | 2006-004032-75 | An open-label, multi-center study to demonstrate the efficacy and safety of C.E.R.A when administered intravenously with pre-filled syringes (PFS) for the treatment of anemia in patients with chronic ... | bad-data | |
| Reported results | 2006-004093-27 | A multicenter, phase II, open-label study evaluating the benefit of addition of MabThera (rituximab) to standard chemotherapies in patients with previously untreated mantle cell lymphoma. | 2011-05-25 | due-trials |
| Reported results | 2006-004407-19 | A multi-center, double-blind, randomized, placebo controlled, dose-ranging phase 2 study to investigate pharmacodynamics, safety, tolerability and pharmacokinetics of RO5073031 in patients with type 2... | 2007-09-06 | due-trials |
| Completed, but no date, and reported results | 2006-004512-43 | Estudio Fase II abierto de Capecitabina (Xeloda®) como fluoropirimidina de elección en combinación con quimioterapia en pacientes con cáncer gástrico Avanzado y/o Metastático susceptibles de ser trata... | bad-data | |
| Reported results | 2006-004552-21 | An open-label, randomized, multi-center, parallel group non-inferiority study of subcutaneous injections of RO0503821 given once monthly vs darbepoetin alfa given according to local label in patient... | 2010-09-15 | due-trials |
| Reported results | 2006-004634-32 | "Estudio de fase III randomizado, abierto del Intergroup: Efecto de la adición de bevacizumab a quimioterapia (QT) basada en fluoropirimidinas como tratamiento en segunda línea de pacientes con cáncer... | 2013-05-31 | due-trials |
| Reported results | 2006-004673-98 | Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blocker | 2009-03-10 | due-trials |
| Reported results | 2006-005144-84 | Essai de phase II évaluant l’efficacité et la tolérance de bevacizumab associé à une chimiothérapie dans le traitement de patients atteints de tumeurs endocrines digestives bien différenciées, progres... | 2011-11-02 | due-trials |
| Reported results | 2006-005147-28 | A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis continuing methotrex... | 2016-04-22 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2006-005330-20 | A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequa... | 2018-05-14 | bad-data |
| Reported results | 2006-005353-30 | A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab in combination with methotrexate (MTX) compared to MTX alone in methotrexate- naïve p... | 2013-08-29 | due-trials |
| Reported results | 2006-005355-16 | A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus | 2011-07-12 | due-trials |
| Reported results | 2006-005357-29 | A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Subjects With WHO or ISN Class III or IV Nephritis ... | 2013-10-28 | due-trials |
| Reported results | 2006-005370-49 | Baltic Post-marketing Program of PEGASYS® (Peg interferon alpha-2a 40KD) in Patients with HBeAg-positive Chronic Hepatitis B | 2010-08-02 | due-trials |
| Reported results | 2006-005520-16 | A multi-center, randomized, double-blind, placebo-controlled phase III trial comparing the efficacy of bevacizumab in combination with rituximab and CHOP (RA-CHOP) versus rituximab and CHOP (R-CHOP) ... | 2012-05-08 | due-trials |
| Reported results | 2006-005619-88 | Estudio Fase II de bevacizumab en combinación con docetaxel y cisplatino, como tratamiento de primera línea de pacientes con cáncer de pulmón no microcítico metastásico o localmente avanzado | 2011-07-18 | due-trials |
| Completed, but no date, and reported results | 2006-005621-28 | A single arm, open label study to assess the efficacy, safety and tolerability of once-monthly administration of intravenous C.E.R.A. for the maintenance of haemoglobin levels in dialysis patients wit... | bad-data | |
| Not reported | 2006-005747-29 | Evaluation of the relationship between HDL quantity and HDL functionality in patients treated with HDL-C raising drugs | 2008-10-10 | due-trials |
| Not reported Terminated | 2006-005965-20 | EFFECTS OF THREE TREATMENT STRATEGIES ON ANEMIA AND QUALITY OF LIFE IN PATIENTS WITH SOLID TUMORS OR LYMPHOPROLIFERATIVE MALIGNANCIES: A RANDOMIZED 3-ARM STUDY ON ACTIVE (A) OR CONVENTIONAL (C) TRANSF... | 2007-04-19 | due-trials |
| Reported results | 2006-006111-77 | Otevřená studie fáze II hodnotící bezpečnost a účinnost indukční analgetické léčby kyselinou ibandronovou (Bondronat) podávanou intravenózně po dobu 15 minut v dávce 6 mg 3 po sobě následující dny pac... | 2008-09-30 | due-trials |
| Completed, but no date, and reported results Terminated | 2006-006263-23 | Efficacy of Oseltamivir treatment in laboratory- confirmed influenza: evaluation of effect on viral shedding and on serum and cytoplasmatic inflammatory cytokine concentration. Efficacia del tratta... | bad-data | |
| Reported results | 2006-006273-25 | A multi-center, double-blind, randomized, placebo-controlled, titration study to investigate the safety, the tolerability and the pharmacodynamic profiles of different doses of RO5073031 in patients w... | 2007-10-24 | due-trials |
| Completed, but no date, and reported results | 2006-006349-15 | A single arm, open label study to assess the efficacy, safety and tolerability of once- monthly administration of intravenous C.E.R.A. for the maintenance of haemoglobin levels in dyalysis patients wi... | bad-data | |
| Reported results | 2006-006359-11 | A Phase II study of Tarceva in Combination with Avastin versus chemotherapy plus Avastin in 1st line advanced NSCLC patients | 2011-05-12 | due-trials |
| Reported results | 2006-006523-40 | A single arm open label study to assess the efficacy, safety and tolerability and of once-monthly administration of subcutaneous C.E.R.A. for the maintenance of haemoglobin levels in pre-dialysis pati... | 2009-06-16 | due-trials |
| Reported results | 2006-006604-11 | A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) When Given in Combination with Pegasys a... | 2009-08-05 | due-trials |
| Reported results | 2006-006707-36 | A single arm, open label study to assess the efficacy, safety, and tolerability of monthly administration of RO0503821 for the treatment of chronic renal anaemia in patients not on dialysis and not cu... | 2010-05-05 | due-trials |
| Completed, but no date, and reported results | 2006-006746-33 | Re-Treatment with Rituximab in patients with rheumatoid arthritis who have had an inadequate response to not more than one aTNF (extension study to ML19070) | bad-data | |
| Reported results | 2006-006865-17 | Estudio multicéntrico, no aleatorizado, abierto, para valorar la eficacia y la seguridad de la combinación de micofenolato mofetilo (MMF), prednisona y eritropoyetina beta en pacientes con síndromes m... | 2009-06-30 | due-trials |
| Reported results | 2007-000126-46 | Einarmige, offene Studie zur Untersuchung der Wirksamkeit, Sicherheit und Verträglichkeit von monatlich subkutan verabreichtem C.E.R.A. an Patienten mit renaler Anämie, die noch nicht dialysepflichtig... | 2010-06-11 | due-trials |
| Reported results | 2007-000172-16 | An open-label study to characterize the safety and response rate of MabThera (Rituximab) plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukemia. | 2012-04-12 | due-trials |
| Reported results | 2007-000175-42 | A double-blind, randomised, multicenter, phase III study of bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin, as first-line t... | 2013-11-30 | due-trials |
| Ongoing | 2007-000226-43 | BONDIR : Bonviva IV dans le traitement des Douleurs liées aux fractures vertébrales ostéoporotiques Récentes. Etude multicentrique, randomisée, comparative en double aveugle contrôlée versus placebo ... | not-yet-due | |
| Reported results | 2007-000348-28 | A single arm, multi-centre, international, continuation trial of recombinant humanized antibody Herceptin® (trastuzumab) in patients with HER2 overexpressing tumors. | 2015-02-11 | due-trials |
| Reported results Terminated | 2007-000593-24 | An Open-Label, Observational Study of the Effects of Anti-TNF Therapy on Peripheral Blood and Synovial Biomarkers in Patients with Active Rheumatoid Arthritis. | 2009-07-10 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2007-000872-18 | A 12- week randomized, double blind, placebo - controlled, parallel group, 2- arm study to evaluate the efficacy and safety of tocilizumab in patients with active systemic juvenile idiopathic arthriti... | 2014-08-05 | bad-data |
| Exempt, with results | 2007-001103-37 | An open-label, multicentre, non-randomised, dose-escalating phase I/II study, with a randomized phase II part, to investigate the safety and tolerability of RO5072759 given as monotherapy in patients ... | 2012-07-03 | not-yet-due |
| Reported results | 2007-001105-13 | A randomised, multicenter, multinational Phase II study on trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus pertuzumab versus trastuzumab plus pertuzumab in patients with locally adv... | 2014-12-19 | due-trials |
| Reported results | 2007-001114-17 | A Mechanism of Action study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) on lipids, arterial stiffness, and markers of atherogenic risk in patients with moderate to severe ... | 2011-01-26 | due-trials |
| Reported results | 2007-001128-11 | An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer. | 2014-09-30 | due-trials |
| Reported results | 2007-001257-25 | Ensayo clínico en fase 2 de búsqueda de dosis, multicéntrico, doble- ciego, aleatorizado y controlado con placebo para investigar la eficacia, seguridad, tolerancia y farmacocinética del inhibidor... | 2008-04-28 | due-trials |
| Reported results | 2007-001585-33 | A randomized, placebo controlled, multicenter clinical study investigating efficacy of rituximab (MabThera/Rituxan) in the inhibition of joint structural damage assessed by magnetic resonance imaging ... | 2014-05-29 | due-trials |
| Completed, but no date, and reported results Terminated | 2007-001720-13 | A single arm, open label study to assess the efficacy, safety and tolerability of once-monthly administration of subcutaneous RO0503821 for the maintenance of haemoglobine levels in patients with chro... | bad-data | |
| Completed, but no date, and reported results Terminated | 2007-001721-97 | An single arm, open label, interventional multicenter study to assess the efficacy, safety and tolerability of once-monthly administration of intravenous C.E.R.A. for the maintenance of haemoglobin le... | bad-data | |
| Completed, but no date, and reported results | 2007-001754-11 | Pilot study to evaluate the effect of Rituximab in combination with MTX in the inhibition of progression of synovitis, bone marrow edema, and erosions evaluated by magnetic resonance imaging (MRI) in ... | bad-data | |
| Ongoing | 2007-001904-18 | An open label randomised controlled study to compare the efficacy, safety and tolerability of once every four weeks administration of subcutaneous C.E.R.A. versus darboepoetin alfa for the maintenance... | not-yet-due | |
| Reported results | 2007-001905-10 | "Estudio abierto, randomizado, controlado para comparar la eficacia, seguridad y tolerancia de la administración una vez cada cuatro semanas de C.E.R.A por vía subcutánea frente a darbepoetina alfa pa... | 2009-07-31 | due-trials |
| Reported results | 2007-002065-12 | "Estudio abierto, randomizado, controlado para comparar la eficacia, seguridad y tolerancia de la administración una vez al mes de C.E.R.A por vía intravenosa frente a epoetina alfa para el mantenimie... | 2010-01-20 | due-trials |
| Reported results | 2007-002135-83 | An open label study to evaluate the effect of first line treatment with Tarceva in combination with Gemcitabine on disease progression in patients with unresectable advanced and/or metastatic non-smal... | 2011-08-12 | due-trials |
| Reported results | 2007-002380-27 | A single arm open label study to assess the efficacy, safety and tolerability and of once-monthly administration of intravenous C.E.R.A. for the maintanance of haemoglobin levels in dialysis patients ... | 2009-07-29 | due-trials |
| Reported results | 2007-002403-41 | Etude clinique ouverte randomisée évaluant le traitement préventif par doxycycline sur la survenue d’éruption type folliculite lors du traitement par erlotinib chez les patients atteints d’un cancer b... | 2010-02-23 | due-trials |
| Reported results | 2007-002733-36 | “Estudio multicéntrico, no aleatorizado, abierto, en Fase II, para valorar la eficacia y seguridad de la inducción con Rituximab, Fludarabina, Ciclofosfamida seguido de Rituximab como mantenimiento (R... | 2016-05-20 | due-trials |
| Completed, but no date, and reported results | 2007-002895-32 | A phase II trial assessing Metronidazol Actavis 1% topical cream in the prevention and treatment of Erlotinib associated rash | bad-data | |
| Reported results | 2007-002960-85 | Randomized, double-blind, placebo-controlled add-on trial of the safety and efficacy of RO4917838 in outpatients on olanzapine, quetiapine, risperidone or paliperidone with prominent negative or disor... | 2010-01-27 | due-trials |
| Reported results | 2007-002997-72 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PERTUZUMAB + TRASTUZUMAB + DOCETAXEL vs. PLACEBO + TRASTUZUMAB + DOCETAXEL IN PREVIOUSLY... | 2018-11-23 | due-trials |
| Reported results | 2007-003165-41 | Étude prospective, multicentrique, ouverte et randomisée évaluant l’efficacité et la tolérance de Cellcept® (MMF) avec suivi thérapeutique pharmacologique, tacrolimus et épargne en corticoïdes versus ... | 2011-07-31 | due-trials |
| Ongoing | 2007-003381-18 | Etude multicentrique française, ouverte, non-comparative, évaluant la tolérance clinique et biologique de l’utilisation de l'epoetin beta (NeoRecormon®) chez des patients présentant une anémie au cour... | not-yet-due | |
| Reported results | 2007-003406-10 | A Phase IIB, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of RO4607381 by Measuring Flow Mediated Dilatation in the Brachial Arte... | 2010-05-06 | due-trials |
| Completed, but no date Terminated | 2007-003679-37 | A single arm, open label study to assess the efficacy, safety, and tolerability of once-monthly administration of intravenous C.E.R.A. for the maintenance of haemoglobin levels in haemodialysis pati... | bad-data | |
| Reported results | 2007-003738-40 | A phase II Biomarker Identification Trial for Erlotinib (Tarceva) in Patients with Advanced Pancreatic Carcinoma. | 2015-03-04 | due-trials |
| Reported results | 2007-003751-37 | A Phase II, Dose-Escalation to Rash Trial of Erlotinib (Tarceva®) plus Gemcitabine in Patients With Metastatic Pancreatic Cancer | 2012-02-20 | due-trials |
| Reported results | 2007-003940-30 | A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the treatment of patients with recurrent or refractory Ewing’s sarcoma, osteosarcoma... | 2014-02-19 | due-trials |
| Not reported | 2007-003955-35 | A controlled open label randomised parallel group study to evaluate the efficacy, safety, and tolerability of subcutaneous MIRCERA, versus no ESA therapy, in the treatment of anaemia in CKD patients a... | 2008-05-28 | due-trials |
| Ongoing | 2007-004014-13 | Etude française, randomisée, controlée, parallèle, en ouvert, multicentrique, comparant le maintien du taux d’hémoglobine avec une administration mensuelle de C.E.R.A. (activateur continu du récepteur... | not-yet-due | |
| Reported results | 2007-004169-16 | Estudio fase II multicéntrico, abierto, no aleatorizado para evaluar la eficacia de una combinación con bevacizumab y quimioterapia secuencial, como tratamiento de pacientes con cáncer de mama operabl... | 2011-03-07 | due-trials |
| Ongoing | 2007-004553-29 | Essai en ouvert, randomisé et multicentrique évaluant l’efficacité et la tolérance de l’association de l’Enfuvirtide en cure d’induction de 3 mois à un traitement optimisé (TO) comprenant au moins 2 m... | not-yet-due | |
| Exempt, with results Terminated | 2007-004617-34 | A phase I/II study of Invirase® boosted with Ritonavir in HIV infected infants and children 4 months to less than 6 years old | 2010-03-11 | not-yet-due |
| Exempt, with results Terminated | 2007-004824-19 | Bevacizumab in Chronic Lymphocytic Leukemia: a proof of concept study | 2010-06-24 | not-yet-due |
| Reported results | 2007-004969-18 | Open-label, efficacy and safety study of bevacizumab (Avastin) in combination with XELOX (Oxaliplatin plus Xeloda) for the first-line treatment of patients with locally advanced or metastatic cancer o... | 2011-08-25 | due-trials |
| Reported results | 2007-004993-15 | A Randomized, Open-Label, Multicenter Study Examining the Effects of 24 Versus 48 Weeks of Combination Therapy with PEGASYS® (Peginterferon alfa-2a 40KD) plus COPEGUS® (Ribavirin) on Sustained Virol... | 2012-05-02 | due-trials |
| Trial is partly outside EEC, and reported results | 2007-005017-19 | Estudio abierto, multicéntrico y aleatorizado en fase II para evaluar la adición de bevacizumab a la quimioterapia en niños y adolescentes con diganóstico inicial de sarcoma metastásico de tejidos bla... | 2019-04-30 | bad-data |
| Reported results | 2007-005037-11 | An open-label, randomized 2-period crossover study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability of warfarin in combination with oseltamivir in volunteers stabilized o... | 2008-07-10 | due-trials |
| Reported results | 2007-005103-18 | A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndr... | 2012-09-01 | due-trials |
| Reported results | 2007-005129-31 | A randomized, controlled, open-label, multi-centre, parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on... | 2017-07-27 | due-trials |
| Reported results | 2007-005182-35 | A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemoth... | 2014-04-17 | due-trials |
| Completed, but no date, and reported results | 2007-005528-34 | Subcutaneous Treatment of Anemia in patients with a GFR Below 45 ml/min/1.73m2 through Injections with Mircera as low frequent as Once monthly | bad-data | |
| Ongoing | 2007-005757-28 | Etude française multi-centrique évaluant le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de C.E.R.A. (activateur continu du récepteur de l’érythropoïétine) chez des pa... | not-yet-due | |
| Reported results | 2007-005759-41 | A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Given as a Single Infusion or Dual Infusion Compared with Placebo in Patients with... | 2013-08-05 | due-trials |
| Completed, but no date, and reported results | 2007-005799-15 | A single arm, open label study to assess the efficacy, safety and tolerability of once-monthly administration of intravenous C.E.R.A. for the maintenance of haemoglobin levels in haemodialysis patient... | bad-data | |
| Exempt, with results | 2007-005939-28 | Estudio de fase I/II multicéntrico, abierto, de escalada de dosis, para evaluar la seguridad, farmacocinética y actividad de RO5083945, un anticuerpo glico-modificado anti-EGFR, en pacientes con tumor... | 2011-06-21 | not-yet-due |
| Reported results | 2007-006231-31 | A mono center, open-label glucose clamp study examining the metabolic effect of the frequency of insulin infusion intervals for basal insulin infusion in patients with type 1 diabetes | 2008-03-05 | due-trials |
| Completed, reported early | 2007-006338-32 | Estudio en fase II de búsqueda de dosis, multicéntrico, aleatorio, de grupos paralelos, parcialmente enmascarado, con placebo y Avonex® como fármacos control, para evaluar la eficacia, determinada por... | 2023-11-08 | not-yet-due |
| Reported results | 2007-006611-23 | Open-label, single-arm, phase II study of bevacizumab (AVASTIN) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell carcin... | 2012-12-03 | due-trials |
| Reported results | 2007-007758-70 | An open-label multi-center, multiple dose study to determine the optimum starting dose of intravenous MIRCERA for maintenance treatment of anemia in pediatric patients with chronic kidney disease on h... | 2016-03-29 | due-trials |
| Reported results | 2007-007863-26 | A multicentre randomized phase II study to assess the safety and resectability in patients with primarily unresectable liver metastases secondary to colorectal cancer receiving 1st line treatment eith... | 2013-10-21 | due-trials |
| Completed, but no date, and reported results | 2008-000105-11 | Effectiveness after 4 and 24 weeks and safety of tocilizumab in patients with active RA | bad-data | |
| Reported results | 2008-000587-17 | Estudio abierto, multinacional para evaluar la seguridad, tolerabilidad y eficacia de tocilizumab en pacientes con artritis reumatoide activa en tratamiento con FAMEs no biológicos que tienen una resp... | 2010-03-30 | due-trials |
| Reported results | 2008-000662-23 | A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer, who... | 2012-09-18 | due-trials |
| Completed, but no date, and reported results | 2008-000783-16 | Multicenter, phase II trial assessing the efficacy and safety of bevacizumab (Avastin®) combined to trastuzumab (Herceptin®) based chemotherapy in patients with primary inflammatory HER2+ breast cance... | bad-data | |
| Reported results | 2008-001122-13 | Multi-center, randomized, double-blind, 5-arm parallel group, placebo controlled 4 week study to investigate the safety, tolerability and efficacy of two doses each (near to maximum tolerated dose and... | 2009-08-24 | due-trials |
| Reported results | 2008-001180-11 | An Open-label, single-arm, Phase II study to evaluate the efficacy and the feasibility of bevacizumab (Avastin®) based on a FOLFOXIRI regimen until progression in patients with previously untreated me... | 2014-02-20 | due-trials |
| Reported results | 2008-001249-24 | A multi-center, double-blind, randomized, parallel group, placebo-controlled 12-week study to investigate glycemic parameters of efficacy, safety/ tolerability and pharmacokinetics of five dose levels... | 2009-10-29 | due-trials |
| Completed, but no date, and reported results | 2008-001612-20 | A study of chlorambucil plus MabThera as induction therapy followed in responders by maintenance therapy versus observation on response rate in patients ≥ 60 years with previously untreated chr... | bad-data | |
| Reported results | 2008-001736-12 | A Randomized, double blind study to determine the effect of two dose schedules of R1507 or placebo, both in combination with erlotinib (Tarceva), on progression-free survival in patients with advanced... | 2011-07-25 | due-trials |
| Reported results | 2008-001744-39 | A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo, in patients with type 2 diabetes mell... | 2010-09-23 | due-trials |
| Reported results | 2008-001747-18 | Etude multicentrique évaluant le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de C.E.R.A. (activateur continu du récepteur de l’érythropoïétine) chez des patients insu... | 2011-07-20 | due-trials |
| Reported results | 2008-001762-85 | An open label study to determine the effect of R1507 (RO4858696) plus Tarceva (erlotinib) on progression-free survival in patients with stage IIIB/IV non-small cell lung cancer with progressive diseas... | 2013-04-26 | due-trials |
| Reported results | 2008-001765-28 | A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo in patients with type 2 diabetes melli... | 2010-05-17 | due-trials |
| Reported results | 2008-001847-20 | Estudio aleatorizado, controlado con placebo, para evaluar la seguridad y eficacia de añadir tocilizumab (TCZ) a metotrexato (MTX) frente al cambio a TCZ (controlado con placebo), con la posibilidad d... | 2013-01-10 | due-trials |
| Reported results | 2008-001854-42 | A multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to sitagliptin and plac... | 2011-03-02 | due-trials |
| Reported results | 2008-001855-23 | A multi-center, randomized, open-label, active-controlled study to compare the efficacy, safety and tolerability of taspoglutide (RO5073031) versus insulin glargine in insulin-naive type 2 diabetic ... | 2011-03-21 | due-trials |
| Reported results | 2008-001856-36 | A multicenter, randomized, open label, active-comparator controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to exenatide in patients with type 2 di... | 2011-03-11 | due-trials |
| Reported results | 2008-002022-10 | An open-label, multicenter protocol providing pegylated interferon alfa-2a (PEGASYS) as monotherapy or in combination with ribavirin (COPEGUS) for patients with chronic hepatitis C who have participa... | 2012-03-23 | due-trials |
| Exempt, with results | 2008-002298-11 | Open-label, multicenter, dose-escalation Phase I/II study to evaluate safety, pharmacokinetics and activity of RO5126766, a dual Raf and MEK inhibitor, administered orally as monotherapy in patients w... | 2008-11-17 | not-yet-due |
| Completed, but no date Terminated | 2008-002381-55 | Evaluación de la Eficacia de Rituximab en pacientes con Artritis Reumatoide a través de la medición, por Resonancia Magnética de Mano, de los parámetros clínicos de la enfermedad. Estudio RESONAR. Ef... | bad-data | |
| Reported results | 2008-002819-40 | A randomized, multicenter, Phase II study of the efficacy and safety of trastuzumab-MCC-DM1 vs. trastuzumab (Herceptin®) and docetaxel (Taxotere®) in patients with metastatic HER2-positive breast canc... | 2012-05-24 | due-trials |
| Completed, but no date, and reported results | 2008-003173-40 | A single arm, open label study to assess the efficacy, safety and tolerability of once-monthly administration of subcutaneous C.E.R.A. for the maintenance of haemoglobin levels in pre-dialysis patient... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2008-003283-20 | A single arm, open-label, phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment of patients with HER2-positive locally recurrent or metastatic breast c... | 2013-03-14 | bad-data |
| Reported results | 2008-003460-19 | An open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease. | 2013-03-14 | due-trials |
| Reported results | 2008-003575-47 | A randomized, double-blind, placebo controlled, parallel group study to investigate the effect of Taspoglutide on gastric emptying measured by a paracetamol test after single dose and after multiple d... | 2009-07-27 | due-trials |
| Reported results | 2008-003657-32 | Estudio abierto fase II de bevacizumab en combinación con paclitaxel y gemcitabina como tratamiento de primera línea en pacientes diagnosticados de carcinoma de mama metastasico o localmente avanzado ... | 2011-12-22 | due-trials |
| Completed, but no date, and reported results | 2008-003980-38 | An open label study of the effect of Xeloda and radiotherapy on pathological response rate in patients with locally advanced rectal cancer. | bad-data | |
| Reported results | 2008-004012-13 | A dose ranging, randomized, double blind, parallel-group placebo-controlled multi-center study of RO5313534 used as add-on to donepezil treatment in patients with mild to moderate symptoms of Alzh... | 2010-11-19 | due-trials |
| Reported results Terminated | 2008-004013-94 | A prospective Phase II study to evaluate alterations in molecular biomarkers in HER2-positive metastatic breast cancer together with assessment of trastuzumab use beyond progression after initial expo... | 2013-02-18 | due-trials |
| Completed, but no date, and reported results | 2008-004126-16 | Local Open-Label Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs who have an Inadequate Response to Current Non-... | bad-data | |
| Exempt, with results Terminated | 2008-004128-22 | An exploratory study to evaluate the biological activity of R1507, a human monoclonal antibody, antagonist of the insulin-like growth factor receptor (IGF-1R) in women with operable breast cancer | 2010-02-15 | not-yet-due |
| Reported results | 2008-005525-11 | A randomized, placebo controlled, double-blind, parallel group study to compare the safety and efficacy of the combination of rituximab (MabThera) and tocilizumab (Actemra) versus tocilizumab therapy ... | 2013-03-13 | due-trials |
| Reported results | 2008-005713-22 | A RANDOMIZED, MULTICENTER, PHASE III OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB-MCC-DM1 VS. CAPECITABINE+LAPATINIB IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BR... | 2015-11-03 | due-trials |
| Exempt, with results | 2008-005806-38 | A multiple ascending dose study to evaluate the safety, tolerability and effect on tumor response of the mTOR inhibitor (RAD001) in combination with the IGF-1R antagonist (R1507) in patients with adva... | 2013-06-06 | not-yet-due |
| Reported results | 2008-005809-20 | A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo in obese patients with type 2 diabetes... | 2010-05-19 | due-trials |
| Reported results | 2008-006146-26 | A randomized, double blind, placebo controlled, multicenter Phase III trial of bevacizumab, temozolomide and radiotherapy, followed by bevacizumab and temozolomide versus placebo, temozolomide and ... | 2015-09-15 | due-trials |
| Reported results Terminated | 2008-006384-37 | A phase II study of orally administered RO4929097, a gamma-secretase inhibitor, as a single agent in patients with recurrent or refractory Non-Small Cell Lung Cancer (NSCLC). | 2010-08-16 | due-trials |
| Completed, but no date, and reported results | 2008-006443-39 | Estudio piloto de fase II multicéntrico, aleatorizado, en grupos paralelos para comparar la incidencia de las reacciones a la infusión de Tocilizumab en pacientes con AR moderada a grave cuando la inf... | bad-data | |
| Reported results | 2008-006504-33 | Etude multicentrique, en ouvert, non randomisée de phase II évaluant l’efficacité de bevacizumab (Avastin®) associé à paclitaxel/carboplatine en première ligne ou à erlotinib en deuxième ligne de trai... | 2012-10-17 | due-trials |
| Reported results | 2008-006801-17 | A multicenter randomized phase II study to compare the combination trastuzumab and capecitabine, with or without pertuzumab, in patients with HER2-positive metastatic breast cancer that have progres... | 2017-08-07 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2008-006872-31 | A randomized phase III clinical study of bevacizumab plus capecitabine vs. bevacizumab alone as maintenance therapy in patients with HER2-negative metastatic breast cancer that has not progressed duri... | 2014-06-14 | bad-data |
| Reported results | 2008-006924-68 | Extension Phase of the Multi-National Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs... | 2012-04-27 | due-trials |
| Reported results | 2008-006946-24 | A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5x10E7pfu RO5217790 in patients with high gr... | 2013-09-17 | due-trials |
| Reported results | 2008-007008-27 | Estudio abierto de terapia de mantenimiento con bevacizumab (AVASTIN) con o sin pemetrexed tras una quimioterapia de primera línea con bevacizumab-cisplatino-pemetrexed en pacientes con cáncer de pulm... | 2012-05-25 | due-trials |
| Completed, but no date, and reported results Terminated | 2008-007057-12 | A Randomized open label study of the effect of first line combination treatment with Avastin (bevacizumab) plus paclitaxel and gemcitabine Compared With Avastin (bevacizumab) plus paclitaxel on ob... | bad-data | |
| Reported results | 2008-007326-19 | A phase III, randomized, open-label study to compare pharmacokinetics, efficacy and safety of subcutaneous (SC) trastuzumab with intravenous (IV) trastuzumab administered in women with HER2 positive e... | 2017-01-24 | due-trials |
| Reported results | 2008-007349-30 | Open-label, phase II, randomized, comparative, multicentre trial of concurrent Whole Brain Radiation Therapy (WBRT) and capecitabine (Xeloda®) followed by maintenance capecitabine compared with standa... | 2011-02-11 | due-trials |
| Ongoing | 2008-007350-35 | A single arm, open-label trial assessing the effect of Capecitabine (Xeloda®) on progression-free survival rate at four months in breast cancer patients with CNS progression after whole brain radiothe... | not-yet-due | |
| Reported results | 2008-007495-20 | A single arm, open-label, multicentre, phase II study to evaluate the efficacy and safety of bevacizumab and trastuzumab combination and sequential capecitabine in patients with HER2-positive locally ... | 2011-06-06 | due-trials |
| Reported results | 2008-008258-21 | A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasy... | 2012-01-23 | due-trials |
| Exempt, with results | 2008-008276-14 | A Phase Ib/II, open-label study of the safety, tolerability, and efficacy of trastuzumab-MCC-DM1 in combination with pertuzumab administered intravenously to patients with HER2-positive locally advanc... | 2011-08-11 | not-yet-due |
| Reported results | 2008-008309-23 | Etude clinique comparative en double aveugle versus placebo sur la rapidité d’action du tocilizumab sur le soulagement des patients atteints de polyarthrite rhumatoïde active avec réponse inadéquate a... | 2011-10-04 | due-trials |
| Reported results | 2008-008336-85 | A single-arm Phase II clinical study investigating the addition of bevacizumab to carboplatin and weekly paclitaxel as first-line treatment in patients with epithelial ovarian cancer | 2013-07-29 | due-trials |
| Completed, but no date, and reported results | 2008-008739-27 | Randomised phase II trial of bevacizumab (AVASTIN) in combination with gemcitabine or attenuated doses of cisplatin and gemcitabine as first-line treatment of elderly patients with advanced, metastati... | bad-data | |
| Reported results | 2009-009157-24 | A multicenter, randomized, double blind (double dummy), active comparator controlled study to compare the efficacy, safety and tolerability of taspoglutide versus pioglitazone in type 2 diabetes patie... | 2011-01-31 | due-trials |
| Reported results | 2009-009608-38 | A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in Combination with Pegasys and Copeg... | 2012-01-02 | due-trials |
| Exempt, with results | 2009-010000-28 | An open-label, multi-center study of the safety and tolerability of the combination of Trastuzumab-MCC-DM1 (T-DM1) with docetaxel, and potentially pertuzumab, for treatment for patients with advanced ... | 2013-10-24 | not-yet-due |
| Reported results | 2009-010390-21 | A randomized, open-label, multi-center Phase II trial of bevacizumab and radiotherapy fol-lowed by bevacizumab and irinotecan vs. temozolomide and radiotherapy followed by temo-zolomide monotherapy in... | 2014-08-30 | due-trials |
| Completed, but no date, and reported results | 2009-011105-17 | A single-arm, open-label study of early improvement of anemia and fatigue during treatment with tocilizumab (TCZ) in combination with non biologic DMARDs, in adult patients with moderate to severe act... | bad-data | |
| Reported results | 2009-011400-33 | A multi-centre, open-label, randomised, two-arm Phase III trial of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or ... | 2014-08-29 | due-trials |
| Completed, but no date, and reported results Terminated | 2009-011433-27 | A phase II multicenter open-label study of MabThera (Rituximab) addition to regularly prescribed chemotherapy in patients with untreated Mantle Cell Lymphoma | bad-data | |
| Completed, but no date, and reported results | 2009-011520-53 | Evaluation of Adherence and Persistence to Tocilizumab in combination with Methotrexate or Tocilizumab Monotherapy in patients with moderate to severe active rheumatoid arthritis in local environment | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2009-011593-15 | A 24 week randomized double-blind, placebo controlled withdrawal trial with a 16 week open label lead-in phase, and 64 week open label follow-up, to evaluate the efficacy and safety of tocilizumab in ... | 2013-08-02 | bad-data |
| Reported results | 2009-012019-17 | A randomised, multicentre, multinational Phase II study to evaluate pertuzumab in combination with trastuzumab given either concomitantly or sequentially with standard anthracycline based chemotherapy... | 2016-01-25 | due-trials |
| Reported results | 2009-012072-28 | A randomized Phase IIIb study of MabThera ® (rituximab) added to a chemotherapy, bendamustine or chlorambucil, in patients with Chronic Lymphocytic Leukemia. | 2014-03-31 | due-trials |
| Reported results | 2009-012090-36 | A single-arm, open-label phase II study: Treatment beyond progression by adding Bevacizumab to XELOX or FOLFOX chemotherapy in patients with metastatic colorectal cancer and disease progression, under... | 2012-01-16 | due-trials |
| Completed, but no date, and reported results | 2009-012185-32 | Open label, multicentric phase IIIb study to evaluate the effect of tocilizumab in combination with DMARDs in the inhibition of progression of synovitis, bone marrow edema, and erosions evaluated by d... | bad-data | |
| Reported results | 2009-012218-30 | A randomized, double-blind, placebo-controlled study to assess the efficacy of tocilizumab (TCZ) + non-biological DMARD in reducing synovitis as measured by magnetic resonance imaging (MRI) at 12 week... | 2011-09-30 | due-trials |
| Reported results | 2009-012231-15 | Pharmacokinetics of Mycophenolate Mofetil in de novo lung allograft recipients | 2012-06-06 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2009-012269-71 | Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D) | 2013-11-18 | bad-data |
| Reported results | 2009-012270-12 | Effects of 150 μg aleglitazar on renal function in patients with Type 2 diabetes and moderate renal impairment, as compared to Actos. | 2012-07-05 | due-trials |
| Reported results | 2009-012293-12 | BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Phase III Study in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma with V600E BRAF Mutation Receiving RO51854... | 2015-07-08 | due-trials |
| Reported results | 2009-012355-15 | Vergleich der Pharmakokinetik von Mycophenolatmofetil und Mycophenolat-Natrium bei Calcineurininhibitor-frei behandelten nierentransplantierten Patienten. | 2010-04-16 | due-trials |
| Reported results | 2009-012476-28 | An open-label, multi-center, three arm randomized, phase III study to compare the efficacy and safety of RO5072759 + chlorambucil (GClb), rituximab + chlorambucil (RClb)or chlorambucil (Clb) alone in ... | 2017-08-23 | due-trials |
| Reported results | 2009-012759-12 | A multi-center, randomized, double-blind, parallel group study of the safety, disease remission and prevention of structural joint damage during treatment with tocilizumab (TCZ), as a monotherapy and ... | 2013-07-15 | due-trials |
| Completed, but no date, and reported results | 2009-013316-12 | A multi-center, randomized, double blind, placebo controlled study to evaluate remission in DMARD and biological naïve early reumatoid arthritis (RA) subjects treated with tocilizumab (TCZ) plus tigh... | bad-data | |
| Reported results | 2009-013410-26 | An open-label, randomized, multicenter, phase II, comparative, exploratory study on neoadjuvant treatment with trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus bevacizumab according t... | 2017-12-13 | due-trials |
| Reported results | 2009-014279-37 | Open-Label study of bevacizumab (Avastin®) and taxane monotherapy for the first-line treatment of patients with advanced triple-negative breast cancer | 2015-11-27 | due-trials |
| Exempt, with results | 2009-014365-12 | An open label, prospective, pharmacokinetic/pharmacodynamic and safety evaluation of oseltamivir (Tamiflu) in the treatment of infants 0 to < 12 months of age with confirmed influenza infection. | 2014-06-04 | not-yet-due |
| Reported results | 2009-014986-22 | A randomized double blind, placebo-controlled clinical trial to assess the effects of taspoglutide (RO5073031) on cardiovascular outcomes in patients with inadequately controlled type 2 diabetes and e... | 2011-01-31 | due-trials |
| Reported results | 2009-015114-22 | A randomized controlled, single-blind, proof- of- concept-study to investigate the protective effects of early treatment with C.E.R.A. in patients with chronic kidney disease on renal disease progress... | 2015-03-30 | due-trials |
| Reported results | 2009-015845-21 | A multi-center, randomized, blinded, parallel-group study of the reduction of signs and symptoms during monotherapy treatment with tocilizumab 8 mg/kg intravenously versus adalimumab 40 mg subcutaneou... | 2012-01-31 | due-trials |
| Listed as ongoing, but also has a completion date | 2009-016560-36 | A LONG-TERM MONITORING STUDY TO EVALUATE THE PERSISTENCE OF DIRECT ACTING ANTIVIRAL (DAA) TREATMENT-RESISTANT MUTATIONS OR THE DURABILITY OF SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PATIENTS TREATED WI... | 2015-03-31 | bad-data |
| Completed, but no date, and reported results | 2009-017063-42 | Biomarkers Impact On the response to Treatment with Erlotinib in first line non-small cell lung Cancer with EGFR activating mutations | bad-data | |
| Reported results | 2009-017443-34 | A Ph II/III seamless, multi-center, randomized, double-blind, placebo-controlled study of the reduction in signs and symptoms and inhibition of structural damage during treatment with tocilizumab v... | 2011-10-12 | due-trials |
| Reported results | 2009-017488-40 | A randomized, double-blind, parallel-group placebo-controlled study of the safety and reduction of signs and symptoms during treatment with tocilizumab (TCZ) versus placebo in patients with ankylos... | 2011-12-28 | due-trials |
| Reported results Terminated | 2009-017725-19 | A Phase IIIB multicenter, double-blind, randomized, placebocontrolled study, evaluating the effect of treatment with dalcetrapib 600 mg on Atherosclerotic Disease as measured by I. Coronary Intravascu... | 2012-05-07 | due-trials |
| Completed, but no date, and reported results | 2009-017848-14 | Estudio fase II de capecitabina- oxaliplatino-trastuzumab (XELOX-trastuzumab) como tratamiento perioperatorio de pacientes con adenocarcinoma gástrico o de la unión gastroesofágica, resecable (estadio... | bad-data | |
| Reported results | 2009-017905-13 | A randomized, 3 arm, multicentre, phase III study to evaluate the efficacy and the safety of T-DM1 combined with pertuzumab or T-DM1 combined with pertuzumab-placebo (blinded for pertuzumab), versus t... | 2016-09-16 | due-trials |
| Reported results | 2010-018331-18 | A 52 week, Single center, Open-label Study to Evaluate Neutrophil function and survival effects of Tocilizumab (TCZ) in Patients with Active Rheumatoid Arthritis (RA) on Background Non-biologic DMARDs... | 2012-03-06 | due-trials |
| Reported results | 2010-018375-22 | A randomized, double-blind, parallel group study of the safety and effect on clinical outcome of tocilizumab SC versus tocilizumab IV, in combination with traditional disease modifying anti-rheumatoid... | 2013-08-19 | due-trials |
| Reported results | 2010-018476-24 | A prospective double-blind randomized Phase III study of 300 mg vs. 150 mg erlotinib in current smokers with locally advanced or metastatic NSCLC in second-line setting after failure on chemotherapy | 2014-02-07 | due-trials |
| Exempt, with results | 2010-018945-72 | A randomized, multicenter, open-label phase Ib/II study of RO5083945 in combination with cisplatin and gemcitabine/pemetrexed versus cisplatin and gemcitabine/pemetrexed in patients with advanced or r... | 2013-07-30 | not-yet-due |
| Reported results | 2010-019051-21 | Estudio de un único brazo, fase II de bevacizumab en combinación con temozolomida en pacientes con glioblastoma multiforme recurrente | 2013-05-31 | due-trials |
| Reported results | 2010-019525-34 | GLOBAL STUDY TO ASSESS THE ADDITION OF BEVACIZUMAB TO CARBOPLATIN AND PACLITAXEL AS FRONT-LINE TREATMENT OF EPITHELIAL OVARIAN CANCER, FALLOPIAN TUBE CARCINOMA OR PRIMARY PERITONEAL CARCINOMA | 2015-03-18 | due-trials |
| Reported results | 2010-019584-10 | A Randomized, Open label, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir (RO5190591) Boosted with Low Dose Ritonavir... | 2013-01-16 | due-trials |
| Reported results | 2010-019585-90 | A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (Danoprevir/r) and Copegus, in Combina... | 2013-01-29 | due-trials |
| Reported results | 2010-019694-15 | Act-Alone : An open-label, single-arm study to describe glucocorticoid use in rheumatoid arthritis patients treated with Tocilizumab in daily clinical practice and to evaluate systematic glucocorticoi... | 2013-03-05 | due-trials |
| Reported results | 2010-019752-50 | A multicenter, multinational phase II study to assess the clinical safety and feasibility of T-DM1 sequentially with anthracyline-based chemotherapy, as adjuvant or neoadjuvant therapy for patients wi... | 2013-06-26 | due-trials |
| Reported results | 2010-019895-66 | Estudio multicéntrico, randomizado, doble ciego, controlado con placebo, con grupos de tratamiento paralelos, de dos años de duración, para evaluar el efecto de RO4909832 administrado por vía subcután... | 2020-09-10 | due-trials |
| Reported results | 2010-019912-18 | A randomized, double-blind, parallel-group study of safety and the effect on clinical outcome of tocilizumab SC versus placebo SC in combination with traditional disease modifying anti-rheumatic drugs... | 2013-11-27 | due-trials |
| Completed, but no date, and reported results | 2010-019935-37 | A pragmatic, randomized, parallel group study of the effect on disease remission, work productivity, and tolerability of tocilizumab in combination with DMARDs and individually designed best practice ... | bad-data | |
| Reported results | 2010-020065-24 | A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of cardiovascular events in patients with moderate to... | 2016-03-23 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2010-020083-38 | A Multicenter, Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged ≥ 13 Years. | 2012-09-14 | bad-data |
| Completed, but no date, and reported results | 2010-020229-42 | A randomized phase II trial of erlotinib (TARCEVA) or intermittent dosing of erlotinib and docetaxel in male former smokers with locally advanced or metastatic squamous nonsmall cell lung cancer (N... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2010-020315-36 | A Randomized, Double-Blind, Double Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif) In Patients With Relapsing Multiple Sclero... | 2022-12-31 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2010-020337-99 | A Randomized, Double-Blind (With Respect To Ocrelizumab Dose) And Rater-Blind (Versus Comparator), Parallel-Group Study To Evaluate The Efficacy And Safety Of Two Doses Of Ocrelizumab In Comparison To... | 2022-12-31 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2010-020338-25 | A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis | 2022-12-31 | bad-data |
| Reported results Terminated | 2010-020370-42 | A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant nega... | 2014-02-27 | due-trials |
| Reported results Terminated | 2010-020467-21 | A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant nega... | 2014-06-09 | due-trials |
| Reported results Terminated | 2010-020470-42 | A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant nega... | 2014-04-14 | due-trials |
| Reported results | 2010-020616-11 | Estudio en fase III, multicéntrico, aleatorizado, de 12 semanas, doble ciego, con grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de RO4917838 en pacientes con síntom... | 2014-09-06 | due-trials |
| Reported results Terminated | 2010-020696-23 | Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms... | 2014-06-09 | due-trials |
| Reported results | 2010-020718-26 | Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms... | 2014-11-12 | due-trials |
| Reported results | 2010-020998-16 | A Phase III randomized study evaluating the efficacy and safety of continued and re-induced bevacizumab in combination with chemotherapy for patients with locally recurrent or metastatic breast cancer... | 2015-03-30 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2010-021067-32 | AN OPEN LABEL, MULTICENTER EXTENSION STUDY OF TRASTUZUMAB-MCC-DM1 (T-DM1) ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OTHER ANTI CANCER THERAPIES IN PATIENTS PREVIOUSLY TREATED WITH THE EQUI... | 2013-05-07 | bad-data |
| Reported results | 2010-021120-96 | A study to assess the incidence of mutations in the tyrosine kinase domain of the epidermal growth factor receptor in UK patients with newly diagnosed locally advanced or metastatic non-small cell lu... | 2014-04-24 | due-trials |
| Exempt, with results Terminated | 2010-021172-28 | Farmacocinética y seguridad de valganciclovir en pacientes pediátricos < 4 meses de edad, receptores de trasplante cardíaco. Pharmacokinetics and safety of valganciclovir in pediatric heart transplant... | not-yet-due | |
| Completed, but no date, and reported results Terminated | 2010-021191-29 | A multicenter, open label study to assess the effect of trastuzumab + Whole Brain Radiotherapy (WBRT) on brain metastases from HER-2 positive breast cancer. | bad-data | |
| Reported results | 2010-021377-36 | A two stage phase III, international, multi center, randomized, controlled, open-label study to investigate the pharmacokinetics, efficacy and safety of rituximab SC in combination with CHOP or CVP ve... | 2017-10-31 | due-trials |
| Reported results | 2010-021984-33 | A phase II/III, multi-center, randomized, 4-week, double-blind, parallel group, placebo and active-controlled trial of the safety and efficacy of RO4917838 vs. placebo in patients with an acute exacer... | 2012-09-10 | due-trials |
| Reported results | 2010-022049-88 | "Efficacy and safety study of a sequential therapy of tocilizumab (TCZ) and, if initially inade-quately responded to tocilizumab (TCZ), followed by rituximab (RTX) in DMARD-IR patients with rheumatoid... | 2014-02-19 | due-trials |
| Reported results | 2010-022067-35 | INFORM-SVR: A Randomized, Multi-Center Study of Interferon-Free Treatment with a Combination of a Polymerase Inhibitor (RO5024048) and a Ritonavir boosted HCV Protease Inhibitor (RO5190591/r, DNV/r) w... | 2012-10-16 | due-trials |
| Trial is partly outside EEC, and reported results | 2010-022189-28 | A PHASE II OPEN-LABEL, RANDOMIZED, MULTI- CENTRE COMPARATIVE STUDY OF BEVACIZUMAB-BASED THERAPY IN PAEDIATRIC PATIENTS WITH NEWLY DIAGNOSED SUPRATENTORIAL, INFRATENTORIAL CEREBELLAR, OR PEDUNCULAR HIG... | 2020-01-29 | bad-data |
| Reported results | 2010-022509-17 | Phase II, open-label study of erlotinib (Tarceva®) treatment in patients with locally advanced or metastatic non-small cell lung cancer who present activating mutations in the tyrosine kinase domain o... | 2017-09-29 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2010-022514-47 | Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients | 2013-05-23 | bad-data |
| Reported results | 2010-022529-14 | A phase III, double-blind, randomized, placebo-controlled, multi-center study evaluating the efficacy and safety of dalcetrapib on lipids, lipoproteins, apolipoproteins and markers of CV risk in patie... | 2012-03-26 | due-trials |
| Reported results | 2010-022645-14 | An open-label, randomized, Phase IIIb trial evaluating the efficacy and safety of standard of care +/- continuous bevacizumab treatment beyond progression of disease (PD) in patients with advanced no... | 2016-06-24 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2010-022902-41 | A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients... | 2024-11-30 | bad-data |
| Reported results | 2010-022983-11 | A randomized, multicenter, open-label phase II study of RO5083945 in combination with FOLFIRI versus FOLFIRI plus cetuximab or FOLFIRI alone as second line treatment in patients with KRAS wild-type... | 2013-12-19 | due-trials |
| Reported results | 2010-023407-95 | A Phase IIIb, randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression and observation in patients with relapsed or refractory, indolent non-Hodgkin's lym... | 2018-06-20 | due-trials |
| Reported results | 2010-023526-21 | An open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma | 2017-02-24 | due-trials |
| Reported results | 2010-023587-40 | A randomized, double-blind, parallel-group study of the reduction of signs and symptoms during treatment with tocilizumab versus adalimumab, both in combination with MTX, in patients with moderate ... | 2012-08-30 | due-trials |
| Reported results | 2010-023763-17 | A phase II double-blind placebo-controlled randomized study of GDC- 0941 or GDC-0980 with Fulvestrant versus Fulvestrant in advanced or metastatic breast cancer in patients resistant to aromatase in... | 2016-04-07 | due-trials |
| Reported results Terminated | 2010-023869-21 | A study of erlotinib (Tarceva®) treatment in patients with locally advanced or metastatic non-small cell lunf cancer who present activating mutations in the tyrosine kinase domain of the epidermal gro... | 2013-10-11 | due-trials |
| Completed, but no date, and reported results | 2010-023892-24 | Phase II, open-label study of erlotinib (Tarceva) treatment In patients with locally advanced or metastatic non-small-cell lung cancer who present activating mutations in the tyrosine kinase domain of... | bad-data | |
| Reported results | 2010-024061-48 | Phase II, open-label study of erlotinib (Tarceva®) treatment in patients with locally advanced, metastatic or recurrent non-small cell lung cancer who present activating mutations in the tyrosine kina... | 2014-01-10 | due-trials |
| Reported results | 2010-024099-25 | A randomized, multi-center cross-over study to evaluate patient preference and Health Care Professional (HCP) satisfaction with subcutaneous (SC) administration of trastuzumab in HER2-positive early... | 2015-12-07 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2010-024132-41 | A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED INDOLENT NON-HODGKIN'S LYMPHOMA EVALUATING THE BENEFIT OF GA101 (RO5072759) PLUS CHEMOTHERAPY COMP... | 2023-11-09 | bad-data |
| Reported results | 2010-024133-23 | An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor RO5185426 in Patients with Metastatic or Unresectable Papillary Thyroid Cancer (PTC) positive for the BRAF V600 Mutation and Resistant ... | 2015-05-29 | due-trials |
| Reported results | 2010-024194-39 | A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED TRIAL COMPARING THE EFFICACY OF GA101 (RO5072759) IN COMBINATION WITH CHOP (G-CHOP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS... | 2018-01-31 | due-trials |
| Reported results | 2010-024468-16 | A randomized, double-blind, placebo-controlled Phase III study of first-line maintenance Tarceva vs Tarceva at the time of disease progression in patients with advanced non-small cell lung cancer (NSC... | 2016-01-22 | due-trials |
| Reported results | 2011-000195-34 | A single arm, open-label, phase II, multicentre study to assess the safety of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma (BCC). Studio multicentrico... | 2017-07-14 | due-trials |
| Reported results | 2011-000509-29 | A Phase III randomized, multicenter, two-arm, open-label trial to evaluate the efficacy of T-DM1 compared with treatment of physician's choice in patients with HER2-positive metastatic breast cancer... | 2015-08-31 | due-trials |
| Exempt, with results | 2011-000640-24 | A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of the HCV N... | 2011-12-08 | not-yet-due |
| Reported results | 2011-000874-67 | An open-label, multicenter, single-arm, Phase I dose-escalation with efficacy tail extension study of RO5185426 in pediatric patients with surgically incurable and unresectable Stage IIIC or Stage IV ... | 2015-12-18 | due-trials |
| Reported results | 2011-000954-46 | An open-label, single-arm, phase II, multicenter study to evaluate the efficacy of vemurafenib in metastatic melanoma patients with brain metastases | 2015-07-30 | due-trials |
| Ongoing | 2011-001096-39 | An International, Multi-Center Study Evaluating the Correlation of IL28B Genotypes with Chronic Hepatitis C Disease Characteristics and Patient Demographics Medzinárodné, multicentrické klinické sk... | not-yet-due | |
| Completed, but no date, and reported results | 2011-001097-25 | Long-term, interventional, open label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Germany who completed the ... | bad-data | |
| Reported results | 2011-001256-10 | Open-label, multicenter phase IV study of ribavirin (Copegus®) combined with standard treatment to assess correlation between hemoglobin decrease and rate of sustained virological response in patients... | 2014-01-22 | due-trials |
| Completed, but no date, and reported results | 2011-001363-46 | RANDOMIZED, NON COMPARATIVE PHASE II TRIAL WITH BEVACIZUMAB AND FOTEMUSTINE IN THE TREATMENT OF RECURRENT GLIOBLASTOMA. STUDIO RANDOMIZZATO, NON COMPARATIVO DI FASE II CON BEVACIZUMAB E FOTEMUSTINA... | bad-data | |
| Completed, but no date, and reported results | 2011-001364-22 | A multi-center, open-label clinical trial to evaluate the objective response rate of bevacizumab in combination with modified FOLFOX-6 followed by one year of maintenance with bevacizumab alone in pat... | bad-data | |
| Completed, but no date, and reported results | 2011-001365-40 | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of 2 Doses of RO4905417 (R1512) Administered to Patients with Non ST-Elevation Myocardial Infarcti... | bad-data | |
| Reported results | 2011-001436-33 | A randomized, double-blind, parallel-group study of the safety and efficacy of RO4917523 versus placebo, as adjunctive therapy in patients with major depressive disorder with inadequate response to on... | 2013-11-22 | due-trials |
| Reported results | 2011-001460-22 | A Phase II/III, Multicenter, Randomized, Double Blind, Placebo-Controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis | 2015-06-16 | due-trials |
| Reported results Terminated | 2011-001526-19 | A randomized, open-label, multicenter Phase IIIb study comparing two trastuzumab dosing regimens, each in combination with cisplatin/ capecitabine chemotherapy, as first-line therapy in patients with ... | 2015-08-25 | due-trials |
| Completed, but no date, and reported results | 2011-001626-15 | A multi-centre, randomized, double-blind study of the safety and efficacy of tocilizumab (TCZ) in combination with methotrexate (MTX), versus TCZ (placebo controlled) in patients with active rheumatoi... | bad-data | |
| Reported results | 2011-001863-39 | A multi-center study of the safety and effect on disease activity of Tocilizumab (TCZ) in combination with Methotrexate (MTX) versus Tocilizumab monotheraphy in patients with mild to moderate rheumato... | 2014-02-13 | due-trials |
| Not reported Terminated | 2011-001891-21 | A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients with Stable Coronary Hear... | 2012-05-07 | due-trials |
| Reported results | 2011-002009-31 | A single arm open label multicentre extension study of bevacizumab in patients with solid tumours on study treatment with bevacizumab at the end of a F. Hoffmann-La Roche and/or Genentech sponsored ... | 2019-09-27 | due-trials |
| Reported results | 2011-002132-10 | A randomized, two-arm, open-label, multicenter Phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first line patients w... | 2019-11-14 | due-trials |
| Reported results | 2011-002160-24 | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of RO4995819 Versus Placebo, as Adjunctive Therapy in Patients with Major Depr... | 2014-06-04 | due-trials |
| Reported results | 2011-002168-26 | OPEN LABEL STUDY OF ERLOTINIB (TARCEVA®) AS SINGLE AGENT FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC LUNG ADENOCARCINOMA WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR... | 2015-01-30 | due-trials |
| Reported results | 2011-002331-25 | An Open-Label, Randomized, Multicenter Phase IIa Study Evaluating Pertuzumab in Combination with Trastuzumab and Chemotherapy in Patients with HER2-Positive Advanced Gastric Cancer | 2017-10-31 | due-trials |
| Reported results | 2011-002363-15 | Multicenter, randomized, parallel group study to compare the incidence of Tocilizumab related infusion reactions in patients with moderate to severe active RA, when infusion is given over 31 minutes c... | 2013-09-02 | due-trials |
| Reported results | 2011-002714-37 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION... | 2014-02-04 | due-trials |
| Reported results | 2011-002715-28 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION... | 2014-01-30 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2011-002732-70 | A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control in Children with HBeAg Positive Chronic Hepatitis B in the... | 2021-12-18 | bad-data |
| Reported results | 2011-003308-18 | A two-cohort, open-label, multicenter Phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab and vinorelbine in first line patients with HER2-positive adv... | 2015-10-15 | due-trials |
| Reported results | 2011-003574-84 | A Randomized, Placebo-controlled, Double-blind, Multicenter Phase II Trial of Intravenous GC33 at 1600 mg Q2W in Previously Treated Patients with Unresectable Advanced or Metastatic Hepatocellular Car... | 2015-08-20 | due-trials |
| Reported results Terminated | 2011-003617-42 | An adaptive, multi-center, randomized, investigator-masked, subject-masked, multiple-dose, placebo-controlled, parallel study to investigate efficacy, safety, tolerability and pharmacokinetics of RO50... | 2012-11-19 | due-trials |
| Reported results | 2011-003719-42 | A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF MetMAb IN COMBINATION WITH EITHER BEVACIZUMAB + PLATINUM + PACLITAXEL OR PEMETREXED + ... | 2015-11-30 | due-trials |
| Reported results | 2011-003720-12 | A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF MetMAb IN COMBINATION WITH PACLITAXEL + CISPLATIN OR CARBOPLATIN AS FIRST-LINE TREATME... | 2015-09-20 | due-trials |
| Reported results | 2011-004011-24 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB (RO5185426) ADJUVANT THERAPY IN PATIENTS WITH SURGICALLY RESECTED, CUTANEOUS BRAF-MUTANT MELANOMA AT HIGH RISK FOR RECU... | 2018-07-13 | due-trials |
| Reported results | 2011-004129-28 | Study To Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Ritonavir-Boosted DANOPREVIR in Combination With Peginterferon Alfa-2a Plus Ribavirin in Treatment-naive Patients and... | 2013-08-28 | due-trials |
| Completed, but no date Terminated | 2011-004205-24 | A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of LEBRIKIZUMAB in patients with uncontrolled asthma who are on inhaled corticosteroids and second c... | bad-data | |
| Reported results | 2011-004218-41 | A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of LEBRIKIZUMAB in patients with uncontrolled asthma who are on inhaled corticosteroids and second co... | 2012-10-01 | due-trials |
| Reported results | 2011-004349-42 | A randomized, double-blind, 12- week, parallel group, placebo-controlled study of the efficacy and safety of RO4917523 in patients with Fragile X Syndrome. | 2014-04-04 | due-trials |
| Reported results | 2011-004426-10 | An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancers | 2016-10-27 | due-trials |
| Reported results | 2011-004810-41 | An international, multicenter, open-label study evaluating sustained virological response and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in tr... | 2014-06-20 | due-trials |
| Reported results Terminated | 2011-005260-20 | Randomised, Phase IV, placebo-controlled, comparative study to evaluate the efficacy and safety of tapering methotrexate (MTX) dosage versus maintaining the dosage in patients with severe active rheum... | 2014-10-21 | due-trials |
| Reported results | 2011-005328-17 | A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS ADJUVANT THERAPY I... | 2020-02-19 | due-trials |
| Reported results | 2011-005334-20 | A multicenter, open-label, single-arm study of pertuzumab in combination with trastuzumab and a taxane in first line treatment of patients with HER2- positive advanced (metastatic or locally recurrent... | 2019-09-20 | due-trials |
| Reported results Terminated | 2011-005335-97 | A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of bevacizumab, and associated biomarkers, in combination with paclitaxel compared wi... | 2017-11-21 | due-trials |
| Reported results | 2011-005912-27 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB IN COMBINATION WITH BEVACIZUMAB OR ONARTUZUMAB MONOTHERAPY IN PATIENTS WITH... | 2016-01-21 | due-trials |
| Reported results | 2011-005975-17 | A two-part, randomized Phase II, double-blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in wo... | 2016-04-28 | due-trials |
| Reported results | 2011-006022-25 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB IN SUBJECTS WITH GIANT CELL ARTERITIS | 2018-06-04 | due-trials |
| Reported results | 2011-006125-14 | A MULTICENTER, OPEN-LABEL, SINGLE ARM, LONG TERM EXTENSION STUDY OF WA19926 TO DESCRIBE SAFETY DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH EARLY, MODERATE TO SEVERE RHEUMATOID ARTHRITIS A WA... | 2014-12-18 | due-trials |
| Completed, but no date, and reported results | 2012-000080-25 | A Phase IIb, Open Label, Single Arm, Multicenter Study to Evaluate the Effect of 48-weeks Peginterferon alfa-2a (PEG-IFN) Administration on Serum HBsAg in Chronic Hepatitis B, HBeAg-Negative, Genotype... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2012-000180-25 | A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma who are on inhaled corti... | 2016-12-28 | bad-data |
| Reported results | 2012-000190-24 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TO ASSESS THE ORAL CORTICOSTEROID?SPARING EFFECT OF LEBRIKIZUMAB IN PATIENTS WITH SEVERE CORTICOSTEROID-DEPENDENT ASTHMA. ... | 2016-12-21 | due-trials |
| Reported results | 2012-000444-10 | A PHASE IV STUDY TO EVALUATE DECREASED DOSE FREQUENCY IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) WHO EXPERIENCE LABORATORY ABNORMALITIES DURING TREATMENT WITH TOCILIZUMAB | 2019-10-09 | due-trials |
| Reported results | 2012-000638-21 | A Randomized, Open-Label, Multicenter Study of the Safety, Efficacy, and Tolerability of Combination Treatment of Setrobuvir, Danoprevir, Ritonavir, and Copegus® with or without Mericitabine in Treatm... | 2013-11-28 | due-trials |
| Reported results | 2012-000660-22 | A randomized, multicenter, adaptive phase II/III study to evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) versus taxane (docetaxel or paclitaxel) in patients with previously treate... | 2016-04-30 | due-trials |
| Reported results | 2012-000669-19 | A COMPARATIVE, RANDOMIZED, PARALLEL-GROUP, MULTI-CENTER, PHASE IIIB STUDY TO INVESTIGATE THE EFFICACY OF SUBCUTANEOUS (SC) RITUXIMAB VERSUS INTRAVENOUS (IV) RITUXIMAB BOTH IN COMBINATION WITH CHOP (R-... | 2016-09-16 | due-trials |
| Reported results Terminated | 2012-000671-16 | A Phase 3b Study To Evaluate The Potential Of Aleglitazar To Reduce Cardiovascular Risk In Patients With Stable Cardiovascular Disease And Glucose Abnormalities | 2013-07-10 | due-trials |
| Reported results | 2012-000943-29 | A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RO4602522 ADDED TO BACKGROUND ALZHEIMER'S DISEASE THERAPY IN PATIE... | 2015-06-03 | due-trials |
| Reported results | 2012-001144-22 | A RANDOMIZED, OPEN-LABEL, PHASE II STUDY ASSESSING THE EFFICACY AND THE SAFETY OF BEVACIZUMAB IN NEOADJUVANT THERAPY IN PATIENTS WITH FIGO STAGE IIIC/IV OVARIAN, TUBAL OR PERITONEAL ADENOCARCINOMA, IN... | 2016-08-17 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2012-001402-23 | A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB (MetMAb) IN COMBINATION WITH 5-FLUOROURACIL, FOLINIC ACID, AND OXALIPLATI... | 2015-12-01 | bad-data |
| Exempt, with results | 2012-001547-46 | Phase I followed by phase II study of the combination of trastuzumab emtansine (T-DM1) and capecitabine in HER2-positive metastatic breast cancer and HER2-positive locally advanced or metastatic gastr... | 2017-05-31 | not-yet-due |
| Reported results | 2012-001628-37 | A TWO-COHORT, OPEN-LABEL, MULTICENTER, STUDY OF TRASTUZUMAB EMTANSINE (T-DM1) IN HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PATIENTS WHO HAVE RECEIVED PRIOR ANTI-HER2 AND CHEMOTHERAPY-... | 2020-07-31 | due-trials |
| Reported results Terminated | 2012-001639-29 | A single center, double-blind, placebo-controlled, randomized, crossover, phase II study to assess the effect of Aleglitazar on cardiac energetics and function in patients with uncomplicated type 2 di... | 2013-07-10 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2012-002018-37 | A RANDOMIZED, MULTICENTER, OPEN LABEL PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH HER2-POSITIVE PRIMARY BREAST... | 2024-05-23 | bad-data |
| Reported results | 2012-002062-13 | A PHASE IIA, INTERNATIONAL, MULTICENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF 4 x 375 mg/m2 INTRAVENOUS RITUXIMAB IN PEDIATRIC PATIENTS WITH SEVERE GRANULOMATO... | 2018-05-10 | due-trials |
| Completed, but no date, and reported results | 2012-002632-87 | Estudio de extensión a largo plazo de los estudios WA22762 y NA25220, multicéntrico, abierto para evaluar la seguridad y eficacia de tocilizumab subcutáneo en pacientes con artritis reumatoide moderad... | bad-data | |
| Reported results | 2012-002633-11 | AN OPEN-LABEL, RANDOMIZED, ADAPTIVE, TWO-ARM, MULTICENTER TRIAL TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF TWO DOSES OF OSELTAMIVIR (TAMIFLU®) IN THE TREATMENT OF INFLUENZA IN IMMUNOCOMPROMI... | 2018-09-07 | due-trials |
| Reported results Terminated | 2012-002649-39 | A SINGLE-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II STUDY TO ASSESS THE EFFICACY OF ALEGLITAZAR ON INSULIN SENSITIVITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2D) WHO ARE INADE... | 2013-09-03 | due-trials |
| Completed, but no date, and reported results | 2012-002777-56 | Cross-sectional multicenter study evaluating the IL28B polymorphism in patients with HBeAg-negative chronic hepatitis B treated with pegylated interferon alfa-2a in the course of Peg.Be.Liver study ... | bad-data | |
| Reported results | 2012-003008-11 | A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIB PLUS GDC-0973 IN PREVIOUSLY UNTREATED BRAFV600-MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR ME... | 2019-07-21 | due-trials |
| Reported results | 2012-003138-17 | A double-blind, placebo-controlled, randomised, Phase II study evaluating the efficacy and safety of addition of continuous multiple line bevacizumab treatment to lomustine in second (2nd)-line follow... | 2017-06-05 | due-trials |
| Reported results | 2012-003144-80 | A PHASE IV, POSTMARKETING, OPEN-LABEL, EXTENSION (ROLLOVER) STUDY OF VEMURAFENIB IN PATIENTS WITH BRAFV600 MUTATION?POSITIVE MALIGNANCIES PREVIOUSLY ENROLLED IN AN ANTECEDENT VEMURAFENIB PROTOCOL E... | 2020-02-17 | due-trials |
| Reported results | 2012-003230-17 | A RANDOMIZED, OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE PATIENT PREFERENCE WITH SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB VERSUS INTRAVENOUS RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CD20+ DIFFU... | 2016-12-20 | due-trials |
| Reported results | 2012-003305-10 | A randomized, double-blinded, regimen controlled, phase II, multicenter study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomas (BC... | 2016-08-31 | due-trials |
| Reported results | 2012-003442-32 | AN OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE III STUDY IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER RESPONDING TO FIRST LINE TREATMENT WITH INTRAVENOUS TRASTUZUMAB FOR AT LEAST 3 YEARS AND ... | 2019-07-17 | due-trials |
| Trial is partly outside EEC, and reported results | 2012-003486-18 | A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB FOLLOWING SUBCUTANEOUS ADMINISTRATION TO PATIENTS WITH POLYARTICULAR-COURSE J... | 2016-05-19 | bad-data |
| Trial is partly outside EEC, and reported results | 2012-003490-26 | A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB FOLLOWING SUBCUTANEOUS ADMINISTRATION TO PATIENTS WITH SYSTEMIC JUVENILE IDIO... | 2017-06-15 | bad-data |
| Reported results | 2012-003554-83 | A double-blind, placebo-controlled, randomized, multicenter phase III study evaluating the efficacy and safety of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-pos... | 2020-01-30 | due-trials |
| Exempt, with results | 2012-004455-36 | AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER PHASE I/II TRIAL OF RO5424802 GIVEN ORALLY TO NON - SMALL CELL LUNG CANCER PATIENTS WHO HAVE ALK MUTATION AND FAILED CRIZOTINIB TREATMENT | 2017-10-27 | not-yet-due |
| Reported results | 2012-004879-38 | A RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM, PHASE III NEOADJUVANT STUDY EVALUATING TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB COMPARED WITH CHEMOTHERAPY PLUS TRASTUZUMAB AND PERTUZUMAB FOR PATIENTS WIT... | 2018-05-29 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2012-004902-82 | A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCLINE... | 2021-06-04 | bad-data |
| Reported results | 2012-005776-34 | A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY AND ACTIVITY OF DNIB0600A COMPARED TO PEGYLATED LIPOSOMAL DOXORUBICIN ADMINISTERED INTRAVENOUSLY TO PATIENTS WITH PLATINUM-R... | 2016-08-17 | due-trials |
| Reported results | 2013-000054-22 | OPEN-LABEL, PHASE IIIB STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS TOCILIZUMAB (MONOTHERAPY OR COMBINATION THERAPY WITH METHOTREXATE OR OTHER DMARDS) IN PATIENTS WITH ACTIVE RHEUMATOID A... | 2016-08-04 | due-trials |
| Reported results | 2013-000087-29 | A multicenter, open-label, single-arm, phase IIIb, international study evaluating the safety of Obinutuzumab alone or in combination with chemotherapy in patients with previously untreated or relapsed... | 2018-10-08 | due-trials |
| Reported results | 2013-000123-13 | A single arm multi-center study investigating the at home administration of trastuzumab subcutaneous vial for the treatment of patients with HER2-positive early breast cancer | 2017-07-19 | due-trials |
| Reported results | 2013-000175-33 | A Phase III, randomized, double-blind, placebo controlled study to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma who are on inhaled corticosteroids and a second c... | 2016-12-28 | due-trials |
| Reported results | 2013-000176-15 | A Phase III, randomized, double-blind, placebo controlled study to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma who are on inhaled corticosteroids and a second c... | 2017-01-03 | due-trials |
| Completed, but no date, and reported results | 2013-000342-19 | MULTI-CENTER, OPEN LABEL, SINGLE ARM PHASE IIIB STUDY ON SAFETY AND EFFICACY OF SUBCUTANEOUS (SC) TOCILIZUMAB (TCZ) IN MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE (MTX) OR OTHER NON-BIOLOGIC DISEA... | bad-data | |
| Reported results | 2013-000359-42 | Multicenter, open label, phase IIIb study to evaluate the safety and tolerability of subcutaneous tocilizumab as monotherapy and/or in combination with methotrexate or other non-biologic disease modif... | 2016-07-11 | due-trials |
| Reported results | 2013-000568-28 | A PHASE II RANDOMIZED, DOUBLE-BLIND STUDY OF NEOADJUVANT LETROZOLE PLUS GDC-0032 VERSUS LETROZOLE PLUS PLACEBO IN POSTMENOPAUSAL WOMEN WITH ER-POSITIVE/HER2-NEGATIVE, EARLY STAGE BREAST CANCER | 2017-03-13 | due-trials |
| Reported results | 2013-000647-12 | A single arm, multicentre, phase IIIb study to evaluate safety, efficacy and pharmacokinetic (PK) of subcutaneous (SC) rituximab administered during induction phase or maintenance in previously untr... | 2019-05-28 | due-trials |
| Reported results | 2013-000829-31 | A LOCAL, OPEN LABEL, MULTICENTRE, PHASE IIIB STUDY, INVESTIGATING SUBCUTANEOUS TRASTUZUMAB ADMINISTERED AT HOME WITH SINGLE INJECTION DEVICE IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER | 2018-09-14 | due-trials |
| Reported results | 2013-000868-29 | A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB IN COMBINATION WITH ERLOTINIB AS FIRST LINE TREATMENT FOR PATIENTS WITH M... | 2015-04-15 | due-trials |
| Reported results | 2013-000900-41 | A STUDY TO MEASURE SERUM PERIOSTIN, ASTHMA-RELATED BIOMARKERS AND RESPONSE TO PREDNISOLONE IN ADULT AND ADOLESCENT PATIENTS WITH SEVERE ORAL CORTICOSTEROID-DEPENDENT ASTHMA | 2014-04-28 | due-trials |
| Other | 2013-001023-39 | LISAH: AN OPEN-LABEL, RANDOMISED PHASE II STUDY ASSESSING QUALITY OF LIFE ASSOCIATED WITH SUBCUTANEOUS TRASTUZUMAB INJECTED INTO THE THIGH OR UPPER ARM IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANC... | not-yet-due | |
| Completed, but no date, and reported results | 2013-001118-14 | Ensayo Clínico Fase IIIb abierto no-controlado para evaluar la seguridad del cambio de rituximab intravenoso a rituximab subcutáneo durante el tratamiento de primera línea de Linfoma No-Hodgkin Folicu... | bad-data | |
| Reported results | 2013-001141-14 | A PHASE 4, BLOOD SAMPLE COLLECTION STUDY FOR EXPLORATORY EVALUATION OF THE ASSOCIATION OF SINGLE NUCLEOTIDE POLYMORPHISMS WITH TREATMENT RESPONSES FROM SUBJECTS WITH HBEANTIGEN POSITIVE OR NEGATIVE CH... | 2022-04-17 | due-trials |
| Reported results | 2013-001142-34 | A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER A... | 2018-08-31 | due-trials |
| Completed, but no date, and reported results | 2013-001161-16 | NATIONAL PHASE IIIB PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, OPEN LABEL STUDY TO ASSESS THE SAFETY OF SUBCUTANEOUS TRASTUZUMAB AND MOLECULAR BIOMARKERS IN PATIENTS WITH EARLY AND LOCALLY ... | bad-data | |
| Reported results | 2013-001163-24 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS. | 2017-11-06 | due-trials |
| Reported results | 2013-001263-23 | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RO5186582 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS) | 2016-05-06 | due-trials |
| Reported results | 2013-001569-17 | A national, open-label, single-arm, phase IIIB study to evaluate the efficacy of weekly tocilizumab subcutaneous, administered as monotherapy or in combination with methotrexate and/or other DMARDS in... | 2016-07-05 | due-trials |
| Reported results Terminated | 2013-001570-14 | A phase IB/II study to evaluate the safety and efficacy of vismodegib in relapsed/refractory acute myelogenous leukemia (AML) and relapsed/refractory high-risk myelodysplastic syndrome (MDS). | 2014-11-03 | due-trials |
| Reported results | 2013-002007-34 | Tocilizumab SC in patients with active rheumatoid arthritis and inadequate response to DMARDs. A single-arm, open-label study to evaluate safety, tolerability and efficacy. In a sub-group of patients ... | 2016-09-13 | due-trials |
| Completed, but no date, and reported results | 2013-002150-79 | TOSCARA: An open-label, single-arm study to evaluate the efficacy, safety and tolerability of tocilizumab (TCZ) subcutaneous in TCZ-naïve patients with active rheumatoid arthritis | bad-data | |
| Reported results | 2013-002341-11 | A SINGLE BLIND PHASE IV PHARMACODYNAMIC STUDY TO EVALUATE NEUTROPHIL DISTRIBUTION KINETICS AND FUNCTION FOLLOWING SINGLE-DOSE TOCILIZUMAB TREATMENT IN HEALTHY SUBJECTS | 2014-12-10 | due-trials |
| Reported results | 2013-002429-52 | A PHASE IIIb STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF SUBCUTANEOUS (SC) TOCILIZUMAB (TCZ) GIVEN AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE (MTX) OR OTHER NON-BIOLOGICS DMARDs... | 2016-03-09 | due-trials |
| Reported results | 2013-003167-58 | A PHASE II, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCIN... | 2019-01-08 | due-trials |
| Reported results | 2013-003330-32 | A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH PD L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | 2019-01-11 | due-trials |
| Reported results | 2013-003331-30 | A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER ... | 2019-01-09 | due-trials |
| Reported results | 2013-003388-79 | PHASE II TRIAL TO EVALUATE THE EFFICACY OF OBINUTUZUMAB (RO5072759) + BENDAMUSTINE TREATMENT IN PATIENTS WITH REFRACTORY OR RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA ENSAYO CLÍNICO FASE II PARA EVALUA... | 2018-11-19 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-003390-95 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICACY AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH MILD ALZHEIMER’S DISEASE; PART II: OPEN-LABEL EXTENS... | 2021-04-16 | bad-data |
| Exempt, with results | 2013-003749-40 | A Phase Ib/II, open label study evaluating the safery and pharmacokinetics of GDC-0199 (ABT-199) in combination with Rituximab (R) or Obinutuzumab (G) plus cyclophosphamide, doxorubicin, vincristine, ... | 2019-06-28 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2013-003752-21 | A multicenter, randomized, addition to baseline treatment, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of Satralizumab (SA237) in patients with Neuromyelitis Op... | 2021-12-23 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2013-004133-33 | RANDOMIZED, MULTICENTER, PHASE III, OPEN LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT NAÏVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER | 2023-07-13 | bad-data |
| Reported results | 2013-004277-27 | PHASE III, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBOCONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY (INDUCTION OF REMISSION) AND SAFETY OF ETROLIZUMAB COMPARED WITH ADALIMUMAB AND PLACEBO... | 2020-05-25 | due-trials |
| Reported results | 2013-004278-88 | PHASE III, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF ETROLIZUMAB DURING INDUCTION AND MAINTENANCE IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS ... | 2020-04-16 | due-trials |
| Reported results | 2013-004279-11 | PHASE III, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY (INDUCTION OF REMISSION) AND SAFETY OF ETROLIZUMAB COMPARED WITH ADALIMUMAB AND PLACEB... | 2020-03-19 | due-trials |
| Reported results | 2013-004280-31 | PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY (MAINTENANCE OF REMISSION) AND SAFETY OF ETROLIZUMAB COMPARED WITH PLACEBO IN PATIENTS WITH MODERATE... | 2020-06-04 | due-trials |
| Reported results | 2013-004282-14 | PHASE III, RANDOMIZED, MULTICENTER DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB COMPARED WITH INFLIXIMAB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE CO... | 2020-06-23 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-004435-72 | AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIES | 2023-10-05 | bad-data |
| Reported results | 2013-004625-81 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT PATIENTS WITH MILD TO MODERATE ASTHMA. | 2016-01-22 | due-trials |
| Reported results | 2013-005108-32 | A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO5520985 (VANUCIZUMAB) PLUS FOLFOX VERSUS BEVACIZUMAB PLUS FOLFOX IN PATIENTS WITH PREVIOUSLY UNTREATED ... | 2017-02-01 | due-trials |
| Exempt, with results | 2013-005212-98 | LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH POLYARTICULAR-COURSE AND SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS | 2021-11-24 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2013-005486-39 | A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER | 2023-02-28 | bad-data |
| Reported results | 2014-000049-56 | A phase II, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of lebrikizumab in patients with persistent moderate to severe atopic dermatitis that is inadequately... | 2016-04-18 | due-trials |
| Reported results | 2014-000106-35 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY T... | 2018-01-23 | due-trials |
| Reported results | 2014-000107-27 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY T... | 2018-01-29 | due-trials |
| Reported results | 2014-000156-28 | A MULTICENTER, MULTINATIONAL, PHASE II STUDY TO EVALUATE PERJETA® IN COMBINATION WITH HERCEPTIN® AND STANDARD NEOADJUVANT ANTHRACYCLINE-BASED CHEMOTHERAPY IN PATIENTS WITH HER2-POSITIVE, LOCALLY ADVAN... | 2020-08-25 | due-trials |
| Reported results | 2014-000275-14 | A Phase II, randomized, double-blind, placebo-controlled bronchoscopy study to evaluate the effects of Lebrikizumab on airway eosinophilic inflammation in patients with uncontrolled asthma on inhaled ... | 2016-10-13 | due-trials |
| Reported results | 2014-000382-41 | A randomized, double-blind, double-dummy active-comparator, multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris | 2019-10-29 | due-trials |
| Reported results Terminated | 2014-000963-42 | A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of oral vismodegib for the treatment of idiopathic pulmonary fibrosis | 2015-07-17 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-001017-61 | A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST-LINE METASTATIC COLORECTAL CANCER (MODUL) | 2021-03-24 | bad-data |
| Reported results | 2014-001237-83 | A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF TRASTUZUMAB EMTANSINE IN PATIENTS WITH HER2 IHC-POSITIVE, LOCALLY ADVANCED OR METASTATIC NON?SMALL CELL LUNG CANCER WHO HAVE RECEIVED AT LEAST ONE PRIOR CH... | 2018-07-26 | due-trials |
| Exempt, with results | 2014-001361-28 | A Phase Ib/II study evaluating the safety, tolerability and anti-tumor activity of polatuzumab vedotin in combination with rituximab (R) or obinutuzumab (G) plus bendamustine (B) in relapsed or refra... | 2021-10-20 | not-yet-due |
| Reported results | 2014-001458-40 | A MULTICENTER, OPEN-LABEL, SINGLE-ARM SAFETY STUDY OF HERCEPTIN® SC IN COMBINATION WITH PERJETA® AND DOCETAXEL IN TREATMENT OF PATIENTS WITH HER2?POSITIVE ADVANCED BREAST CANCER (METASTATIC OR LOCALLY... | 2019-02-22 | due-trials |
| Exempt, with results | 2014-001498-15 | OPEN-LABEL PHASE Ib/II, MULTICENTER STUDY OF THE COMBINATION OF RO5479599 WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) OF SQUAMOUS HISTOLO... | 2016-03-14 | not-yet-due |
| Other | 2014-001810-24 | A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX (GDC-0199/ABT 199) VERSUS OBINUTUZUMAB AND CHL... | not-yet-due | |
| Ongoing | 2014-002048-42 | An single arm open-label multi-centre extension study of pertuzumab administered as a single agent or in combination with other anti-cancer therapies in patients previously enrolled in a Hoffmann-La R... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2014-002230-32 | A MULTISTAGE, PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF COBIMETINIB PLUS PACLITAXEL, COBIMETINIB PLUS ATEZOLIZUMAB PLUS PACLITAXEL, OR COBIMETINIB PLUS ATEZOLIZUMAB PLUS NAB-PACLITAXEL AS F... | 2021-09-16 | bad-data |
| Exempt, with results | 2014-002246-41 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO6885247 FOLLOWING 12 WEEKS OF TREA... | 2016-12-15 | not-yet-due |
| Exempt, with results | 2014-002835-32 | AN OPEN-LABEL, MULTICENTER, DOSE-ESCALATION PHASE IB STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND THERAPEUTIC ACTIVITY OF RO7009789 (CD40 AGONIST) IN COMBINATION WITH MPDL3... | 2019-11-07 | not-yet-due |
| Reported results | 2014-003065-15 | A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE III STUDY OF IDASANUTLIN, AN MDM2 ANTAGONIST, WITH CYTARABINE VERSUS CYTARABINE PLUS PLACEBO IN PATIENTS WITH RELAPSED OR REFRACTORY ... | 2020-04-24 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-003083-21 | A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) COMPARED WITH A PLATINUM AGENT (CISPLATIN OR CARBOPLATIN) IN COMBINATION WITH EITHER PEMETREXED OR GEMCITABINE FOR PD-L1... | 2022-03-08 | bad-data |
| Reported results | 2014-003106-33 | A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (ANTI− PDL1 ANTIBODY) COMPARED WITH GEMCITABINE+CISPLATIN OR CARBOPLATIN FOR PD-L1−SELECTED, CHEMOTHERAPY NAIVE PATIENTS WITH STAGE IV SQUAMOU... | 2017-12-07 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-003185-25 | A PHASE III, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY OF TASELISIB PLUS FULVESTRANT VERSUS PLACEBO PLUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE AND HER2 NEGATIVE ... | 2021-06-29 | bad-data |
| Other | 2014-003205-15 | A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAP... | not-yet-due | |
| Reported results | 2014-003206-32 | A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (MPDL3280A, ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN+NAB-PACLITAXEL FOR CHEMOTHERA... | 2021-01-18 | due-trials |
| Reported results | 2014-003207-30 | A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (MPDL3280A, ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN + PACLITAXEL WITH OR WITHOUT BEVACIZUMAB COMPARED WITH CARBOPLATIN+PACLITAXEL... | 2020-09-04 | due-trials |
| Reported results | 2014-003208-59 | A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (MPDL3280A, ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN+PACLITAXEL OR ATEZOLIZUMAB IN... | 2021-02-17 | due-trials |
| Reported results | 2014-003231-19 | A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR META... | 2018-11-08 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-003824-36 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY T... | 2021-09-08 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2014-003855-76 | AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144 STUDIO IN APERTO... | 2023-10-09 | bad-data |
| Reported results | 2014-004673-16 | PROSPECTIVE, MULTICENTRE, PLACEBO CONTROLLED, DOUBLE-BLIND STUDY TO COMPARE THE EFFICACY OF MAINTENANCE TREATMENT WITH TOCILIZUMAB WITH OR WITHOUT GLUCOCORTICOID DISCONTINUATION IN RHEUMATOID ARTHRITI... | 2018-02-20 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-004684-20 | A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA NEZASLEPENÉ... | 2021-12-13 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2014-004685-25 | A PHASE I/II, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF COBIMETINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS | 2021-07-21 | bad-data |
| Reported results | 2014-004697-41 | AN EARLY-PHASE, MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ANTI?PD-L1 ANTIBODY (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS ESTUDI... | 2019-06-06 | due-trials |
| Reported results | 2014-005438-69 | AN OPEN-LABEL, MULTICENTER EXTENSION STUDY OF ONARTUZUMAB IN PATIENTS WITH SOLID TUMORS ON STUDY TREATMENT PREVIOUSLY ENROLLED IN AN F. HOFFMANN-LA ROCHE- AND/OR GENENTECH-SPONSORED STUDY | 2018-06-29 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-005490-37 | A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH PREV... | 2021-08-31 | bad-data |
| Reported results | 2014-005491-28 | A MULTICENTRE OPEN-LABEL SINGLE-ARM PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF BEVACIZUMAB IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH METASTATIC, RECURRENT OR PERSISTENT... | 2018-12-31 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-005603-25 | A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-POSITIVE, HIGH RISK MUSCLE INVASIVE UROTHELI... | 2022-06-14 | bad-data |
| Reported results | 2015-000269-30 | AN OPEN-LABEL, MULTICOHORT, PHASE II STUDY OF ATEZOLIZUMAB IN ADVANCED SOLID TUMORS | 2020-07-28 | due-trials |
| Reported results | 2015-000424-28 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS | 2019-02-04 | due-trials |
| Exempt, with results | 2015-000435-33 | A phase I pharmacokinetic and safety study of tocilizumab (TCZ) in patients less than 2 years old with active systemic juvenile idiopathic arthritis (sJIA) | 2017-07-13 | not-yet-due |
| Reported results | 2015-000634-29 | RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS PEMETREXED OR DOCETAXEL IN ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON SMALL CELL LUNG CANCER PATIENTS PREVIOUSLY TREATED ... | 2018-08-13 | due-trials |
| Reported results | 2015-001122-42 | A Phase II, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lebrikizumab in patients with chronic obstructive pulmonary disease and a history of exacerbations | 2017-02-17 | due-trials |
| Exempt, with results | 2015-001364-19 | A phase Ib/II study evaluating the safety and efficacy of MPDL3280A in combination with either obinutuzumab plus bendamustine or obinutuzumab plus CHOP in patients with follicular lymphoma or diffuse ... | not-yet-due | |
| Reported results | 2015-001377-40 | PHASE II, EXPLORATORY, MULTICENTER, NON RANDOMIZED, SINGLE AGENT COHORT STUDY TO DETERMINE BEST TUMOR RESPONSE WITH TRASTUZUMAB EMTANSINE IN HER2 OVEREXPRESSING SOLID TUMORS. | 2018-04-10 | due-trials |
| Reported results | 2015-001589-25 | Multicenter, open-label, single arm study to evaluate long-term safety, tolerability, and effectiveness of 10mg/kg BID olesoxime in patients with Spinal Muscular Atrophy | 2018-12-18 | due-trials |
| Exempt, with results Terminated | 2015-001620-33 | A Phase Ib/III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of vismodegib in combination with ruxolitinib versus placebo and ruxolitinib in patients with int... | not-yet-due | |
| Reported results | 2015-001731-20 | A SINGLE ARM, OPEN LABEL, PHASE II, MULTICENTER STUDY TO ASSESS THE DETECTION OF THE BRAF V600 MUTATION ON cfDNA FROM PLASMA IN PATIENTS WITH ADVANCED MELANOMA | 2019-07-16 | due-trials |
| Exempt, with results | 2015-001998-40 | A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIMAB ... | not-yet-due | |
| Reported results | 2015-001999-22 | A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR DIFFUSE LARGE B-CE... | 2021-12-15 | due-trials |
| Reported results | 2015-002022-39 | A randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety and efficacy of Obinutuzumab in patients with ISN/RPS 2003 class III or IV Lupus Nephritis | 2023-08-02 | due-trials |
| Exempt, with results | 2015-002100-83 | A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH IDASANUTLIN IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND OBINUTUZUMAB OR RITUXIMAB IN COMB... | 2019-05-20 | not-yet-due |
| Exempt, with results | 2015-002467-42 | A phase Ib/II study evaluating the safety and efficacy of Atezolizumab in combination with obinutuzumab plus lenalidomide in patients with relapsed or refractory follicular lymphoma | 2020-10-07 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2015-002866-21 | A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH IN... | 2020-12-01 | bad-data |
| Reported results | 2015-003034-27 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODOMAL-TO-MILD ALZHEIMER?S DISEASE ESTUDIO EN FAS... | 2019-05-31 | due-trials |
| Reported results Terminated | 2015-003227-66 | A randomized, double-blind, placebo-controlled, parallel group, safety, efficacy and pharmacodynamic study of basmisanil (RO5186582) in adults with severe motor impairment following an ischemic stroke... | 2017-12-12 | due-trials |
| Reported results | 2015-003280-11 | AN EXPLORATORY MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF THE SAFETY AND TOLERABILITY OF PIRFENIDONE (ESBRIET®) IN COMBINATION WITH NINTEDANIB (OFEV®) IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS | 2017-05-16 | due-trials |
| Ongoing | 2015-003385-84 | AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK1/2/3, ROS1, OR ALK GENE REARRANGE... | not-yet-due | |
| Exempt, with results Terminated | 2015-003386-28 | A phase Ib/II multi-arm study with venetoclax in combination with cobimetinib, and venetoclax in combination with idasanutlin in patients ≥ 60 years with relapsed or refractory acute myeloid leukemia ... | 2020-07-03 | not-yet-due |
| Trial is outside EEC, and reported results | 2015-003537-99 | A PHASE IV MULTICENTER, RANDOMIZED, OPEN LABEL, TWO-PERIOD CROSSOVER STUDY IN PATIENTS WITH CYSTIC FIBROSIS TO EVALUATE THE COMPARABLE EFFICACY AND SAFETY OF PULMOZYME® DELIVERED BY THE ERAPID™ NEBULI... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2015-003605-42 | A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (MPDL3280A, ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN OR CISPLATIN + PEMETREXED COMPARED WITH CARBOPLATIN OR CISPLATIN + PEMETREXED... | 2022-12-13 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2015-004105-16 | A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH TREATMENT-NA¿VE ADVANCED OR RECURRENT (STAGE I... | 2023-10-25 | bad-data |
| Reported results | 2015-004189-27 | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB-PLACEBO IN PATIENTS WITH... | 2020-02-06 | due-trials |
| Trial is outside EEC, and reported results | 2015-004211-20 | A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma | bad-data | |
| Reported results | 2015-004476-30 | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2A STUDY TO ASSESS THE EFFICACY OF RO5459072 IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME | 2017-10-10 | due-trials |
| Exempt, with results | 2015-004845-25 | A phase Ib/II study evaluating the safety and efficacy of obinutuzumab in combination with atezolizumab plus polatuzumab vedotin in patients with relapsed or refractory follicular lymphoma and rituxim... | 2019-10-07 | not-yet-due |
| Exempt, with results | 2015-004861-97 | A PHASE I/III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB (ANTI PD-L1 ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL... | 2022-07-07 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2015-005131-40 | A PHASE IIb, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATHIC ... | 2020-08-22 | bad-data |
| Reported results | 2015-005431-41 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patients With Neuromyelitis Optica (NMO) and Neuromyelitis Opt... | 2022-01-31 | due-trials |
| Trial is outside EEC, and reported results | 2015-005455-28 | A Multi-Site, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7239361 (BMS-986089) in Ambulator... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2015-005597-38 | An open-label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying... | 2020-12-15 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-000072-17 | A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITHOUT... | 2022-05-12 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-000073-21 | A MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITO... | 2020-11-11 | bad-data |
| Reported results | 2016-000202-11 | A Phase III, open-label, multicenter, three-arm, randomized study to investigate the efficacy and safety of cobimetinib plus atezolizumab and atezolizumab monotherapy vs. regorafenib in patients with ... | 2019-01-14 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-000250-35 | A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI?PD-L1 ANTIBODY) IN COMBINATION WITH GEMCITABINE/CARBOPLATIN VERSUS GEMCITABINE/CARBOPLATIN ALONE IN P... | 2024-02-12 | bad-data |
| Trial is outside EEC, and reported results | 2016-000263-17 | Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection | bad-data | |
| Reported results | 2016-000423-13 | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION WHO HAVE C... | 2018-05-16 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-000750-35 | A TWO-PART SEAMLESS, MULTI-CENTER RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE BLIND STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RISDIPLAM (RO7034067) I... | 2023-10-02 | bad-data |
| Trial is outside EEC, and reported results | 2016-000758-37 | A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2016-000778-40 | A TWO PART SEAMLESS, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7034067 IN INFANTS WITH TYPE1 SPINAL MUSCULAR ATROPHY | 2023-12-22 | bad-data |
| Trial is outside EEC, and reported results | 2016-001001-16 | A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Persistency of Response with or without Xolair after Long-Term Therapy (XPORT) | bad-data | |
| Trial is outside EEC, and reported results | 2016-001008-49 | A randomized, multicenter trial of oseltamivir doses of 75 mg for 5 or 10 days versus 150 mg for 5 or 10 days in influenza patients with pandemic (H1N1) 2009 | bad-data | |
| Trial is outside EEC | 2016-001042-25 | A Study to Investigate the Impact of Pharmacogenetics on CellCept Use, in Patients Participating in a Study in Renal Transplantation | bad-data | |
| Trial is outside EEC, and reported results | 2016-001043-39 | An Open-Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose Vs Concentration Controlled Cellcept Regimens For Patients Following A Single Organ Renal Transplantation In... | bad-data | |
| Trial is outside EEC, and reported results | 2016-001044-18 | A phase IIIb, openlabel, comparative, randomized study on resistance of Influenza A/H1N1 2009 virus to treatment with Oseltamivir at standard dose versus double dose | bad-data | |
| Trial is outside EEC, and reported results | 2016-001045-12 | A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas. | bad-data | |
| Trial is outside EEC, and reported results | 2016-001046-26 | Multiple Ascending Dose (MAD) Phase I Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Children and Adolescents with Advanced Solid Tumors | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2016-001094-33 | A MULTICENTER, OPEN-LABEL, PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB GIVEN EVERY 4 WEEKS (Q4W) IN PATIENTS WITH HEMOPHILIA A | 2022-06-29 | bad-data |
| Trial is outside EEC | 2016-001160-11 | An Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Tacrolimus Ointment in the Treatment of Atopic Dermatitis in Pediatric Patients | bad-data | |
| Reported results | 2016-001654-18 | A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys with Duchenne Muscular Dystrophy Étude randomisée, en doubl... | 2020-04-28 | due-trials |
| Trial is outside EEC | 2016-001661-91 | Open-label Comparative Randomized Study of the Efficacy and Safety of Orlistat (Xenical) in Complex Therapy of Obesity and Metabolic Disorders in Adolescents | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2016-001881-27 | A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy in patients with renal cell carcinoma at high risk of developing ... | 2022-12-08 | bad-data |
| Reported results | 2016-002126-36 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RO7123520 AS ADJUNCT TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMAT... | 2018-11-06 | due-trials |
| Exempt | 2016-002128-10 | An adaptive Phase I/II study to assess safety, efficacy, pharmacokinetics and pharmacodynamics of RO7112689 in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH) | not-yet-due | |
| Exempt, with results Terminated | 2016-002480-34 | A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH IDASANUTLIN AND VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND OBINUTUZUMAB OR RI... | 2020-04-30 | not-yet-due |
| Listed as ongoing, but also has a completion date | 2016-002482-54 | A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PLACEBO PLUS COBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAFV600 MUTA... | 2024-07-01 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-002625-11 | AN OPEN LABEL, SINGLE ARM, MULTICENTER, SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT | 2022-12-12 | bad-data |
| Other | 2016-002667-34 | AN OPEN-LABEL, PARALLEL-GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF OCRELIZUMAB IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROS... | not-yet-due | |
| Reported results | 2016-002716-41 | AN EXTENSION STUDY TO EVALUATE LONG TERM SAFETY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH GIANT CELL ARTERITIS WHO HAVE COMPLETED WA28119 CORE STUDY IN FRANCE, AND SUBSEQUENTLY HAVING FLARE OR PERS... | 2019-08-21 | due-trials |
| Reported results | 2016-002744-17 | MULTICENTER, INTERNATIONAL, DOUBLEBLIND, TWO-ARM, RANDOMIZED, PLACEBO CONTROLLED PHASE II TRIAL OF PIRFENIDONE IN PATIENTS WITH UNCLASSIFIABLE PROGRESSIVE FIBROSING ILD | 2020-01-10 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-002937-31 | An Open-Label, single-arm study to Evaluate the Effectiveness and Safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis STUDIO IN APERTO, A SINGOLO BRACCIO, PER ... | 2023-04-27 | bad-data |
| Trial is outside EEC, and reported results | 2016-003003-54 | An Open-label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir in the Treatment of Infants Less Than One Year of Age With Influenza Infection | bad-data | |
| Trial is outside EEC, and reported results | 2016-003004-31 | An Open Label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir (Tamiflu) in the Treatment of Children 1 to 12 Years of Age With Influenza Infection | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2016-003092-22 | A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CA... | 2022-12-20 | bad-data |
| Trial is outside EEC, and reported results | 2016-003201-34 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis | bad-data | |
| Trial is outside EEC, and reported results | 2016-003260-39 | Intravenous Granisetron (Kytril) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy | bad-data | |
| Reported results | 2016-003288-20 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE | 2019-05-31 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-003472-52 | A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE ... | 2022-08-22 | bad-data |
| Reported results | 2016-003579-22 | A PHASE II STUDY EXPLORING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB ADMINISTERED IN COMBINATION WITH OBINUTUZUMAB OR RITUXIMAB ANTI-CD20 THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOM... | 2022-01-14 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-003695-47 | A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ADJUVANT ANTHRACYCLINE/TAXANE-BASED CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PA... | 2023-08-14 | bad-data |
| Reported results | 2016-003924-22 | AN OPEN-LABEL, MULTICENTER, SINGLE-ARM, PHASE II STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALECTINIB IN PATIENTS WITH ALK-REARRANGED NON−SMALL CELL LUNG CANCER AFTER DISEASE PROGRESSION ON PRIOR ALK ... | 2019-09-26 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-004024-29 | A PHASE III, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WIT... | 2023-03-20 | bad-data |
| Exempt | 2016-004126-42 | A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTA... | not-yet-due | |
| Ongoing | 2016-004184-39 | AN OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS/PHARMACODYNAMICS OF RISDIPLAM (RO7034067) IN ADULT AND PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2016-004366-25 | A SINGLE-ARM, MULTICENTER PHASE IIIB CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PROPHYLACTIC EMICIZUMAB IN HEMOPHILIA A PATIENTS WITH INHIBITORS | 2020-11-19 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-004387-18 | A PHASE III, OPEN-LABEL, MULTICENTER, TWO ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVAN... | 2021-02-19 | bad-data |
| Exempt | 2016-004390-41 | A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors | 2024-03-21 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2016-004429-17 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PRE... | 2024-04-24 | bad-data |
| Ongoing | 2016-004529-17 | A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED UNRESECTA... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2016-004734-22 | A PHASE III RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NEOADJUVANT ANTHRACYCLINE/NAB-PACLITAXEL-BASED CHEMOTHERAPY COMPARED WITH ... | 2022-09-28 | bad-data |
| Reported results | 2016-004779-39 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO ASCERTAIN THE OPTIMAL STARTING DOSE OF MIRCERA® GIVEN SUBCUTANEOUSLY FOR THE MAINTENANCE TREATMENT OF ANEMIA IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY D... | 2021-07-19 | due-trials |
| Completed, but no date, and reported results Terminated | 2016-004799-23 | A PHASE II, SINGLE ARM, MULTICENTER, PROOF OF MECHANISM STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF BITOPERTIN (RO4917838) IN ADULTS WITH NON-TRA... | bad-data | |
| Ongoing | 2016-005119-42 | A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF ATEZOLIZUMAB PLUS CHEMOTHERAPY FOR PATIENTS WITH EARLY RELAPSING RECURRENT (INOPERABLE LOCALL... | not-yet-due | |
| Ongoing | 2016-005189-75 | AN OPEN-LABEL, MULTICENTER EXTENSION AND LONG-TERM OBSERVATIONAL STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH- AND/OR F. HOFFMANN LA ROCHE LTD-SPONSORED ATEZOLIZUMAB STUDY | not-yet-due | |
| Other | 2017-000076-28 | A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER (NSCLC) HARBORING A... | not-yet-due | |
| Other | 2017-000087-15 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015 (PRX002) IN PARTICIPANTS WITH EARLY PARKINSON’S DISEASE WITH A 52 WEEK BLINDED ... | not-yet-due | |
| Ongoing | 2017-000207-24 | A MULTICENTER, INTERNATIONAL, ROLLOVER STUDY OF ALECTINIB IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE OR REARRANGED DURING TRANSFECTION (RET)-POSITIVE CANCER | not-yet-due | |
| Reported results | 2017-000794-37 | A PHASE II, OPEN-LABEL, MULTICENTER, MULTI-COHORT STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB IN PATIENTS WITH SOLID TUMORS | 2020-07-28 | due-trials |
| Reported results | 2017-000830-68 | A PHASE IB/II STUDY OF COBIMETINIB ADMINISTERED AS SINGLE AGENT AND IN COMBINATION WITH VENETOCLAX, WITH OR WITHOUT ATEZOLIZUMAB, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA | 2021-05-18 | due-trials |
| Reported results | 2017-000861-58 | A PHASE II, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF IDASANUTLIN MONOTHERAPY IN PARTICIPANTS WITH HYDROXYUREA-RESISTANT/INTOLERANT POLYCY... | 2020-03-03 | due-trials |
| Exempt | 2017-001267-21 | A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC NONSMALL CELL L... | not-yet-due | |
| Ongoing | 2017-001313-93 | AN OPEN-LABEL, SINGLE-ARM 4 YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS STUDIO IN APERTO, A SINGOLO BRACCIO, DELLA DURAT... | not-yet-due | |
| Reported results | 2017-001364-38 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER'S DISEASE | 2023-02-17 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-001365-24 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER’S DISEASE | 2022-11-28 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-001409-34 | A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL... | 2022-04-07 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-001548-36 | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, ... | 2023-01-04 | bad-data |
| Reported results | 2017-001718-28 | A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2019-03-11 | due-trials |
| Reported results | 2017-001724-22 | A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2019-03-11 | due-trials |
| Reported results Terminated | 2017-001764-37 | A PHASE II, OPEN-LABEL EXTENSION STUDY OF PATIENTS PREVIOUSLY ENROLLED IN STUDY GA30044 TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LU... | 2019-11-18 | due-trials |
| Reported results | 2017-001800-31 | A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF MTAU9937A IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE | 2021-02-15 | due-trials |
| Ongoing | 2017-002023-21 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (RCHP) VERSUS RITUXIMAB AND ... | not-yet-due | |
| Exempt | 2017-002038-21 | A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE ... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2017-002350-36 | A PHASE II, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF UTTR1147A COMPARED WITH PLACEBO AND ... | 2021-12-15 | bad-data |
| Reported results | 2017-002471-25 | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7234292 (ISIS 443139) IN HUNTINGTON'S DISEASE PATIENTS WHO PARTICIPATED IN PRIOR INVESTIG... | 2019-10-08 | due-trials |
| Reported results | 2017-002702-12 | A MULTICENTER, OPEN-LABEL, LONG-TERM EXTENSION OF PHASE III STUDIES (BN29552/BN29553) OF CRENEZUMAB IN PATIENTS WITH ALZHEIMER¿S DISEASE ESTENSIONE A LUNGO TERMINE, MULTICENTRICA E IN APERTO DI STU... | 2019-05-31 | due-trials |
| Ongoing | 2017-002857-12 | A PHASE III, DOUBLE-BLINDED, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT TREATMENT WITH ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN P... | not-yet-due | |
| Ongoing, reported early | 2017-003040-20 | A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemothera... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2017-003182-94 | AN OPEN-LABEL, MULTICENTER, PHASE II STUDY TO EVALUATE THE THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE, CONSISTING OF INTERLEUKIN-2 VARIANT (IL-2V) TARGETING FIBROBLAST ACTIVATION PROTEIN-Α (... | 2021-12-30 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-003302-40 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY AFTER DEFINITIVE LOCAL THERAPY IN PATIENTS WITH HIGH-RISK LOCALLY... | 2024-03-06 | bad-data |
| Reported results | 2017-003450-16 | OPEN-LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | 2020-03-16 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-003649-10 | A PHASE I, OPEN–LABEL, RANDOMIZED, PHARMACOKINETIC, PHARMACODYNAMIC, AND SAFETY STUDY OF ETROLIZUMAB FOLLOWED BY OPEN–LABEL EXTENSION AND SAFETY MONITORING IN PEDIATRIC PATIENTS FROM 4 YEARS TO LESS T... | 2023-09-29 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-003691-31 | A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB COMPARED WITH SORAFENIB IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA | 2022-11-17 | bad-data |
| Ongoing | 2017-004331-37 | A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS = ... | not-yet-due | |
| Reported results | 2017-004378-32 | A phase III, randomized, double-blind, placebo-controlled, efficacy, and safety study of Balovaptan in adults with Autism Spectrum Disorder with a 2 year open-label extension. | 2020-07-06 | due-trials |
| Exempt, with results | 2017-004566-99 | A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC COLORECTAL CANCE... | not-yet-due | |
| Other | 2017-004634-28 | A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN CISPLATIN-INELIGIBLE PATIENTS WITH LOCALL... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2017-004886-29 | A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSORED... | 2021-11-30 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-004897-32 | A phase III, randomized, multicenter, open-label, two-arm study to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous administration of the fixed-dose combination of pertuzumab and tr... | 2023-06-02 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-004997-32 | A PHASE II OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF UTTR1147A IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS OR CROHN'S DISEASE | 2022-07-12 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-005104-10 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB (RO6867461) IN PATIENTS WITH DIABETIC MACULAR EDEMA (YOSEMITE) | 2021-09-03 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-005105-12 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB (RO6867461) IN PATIENTS WITH DIABETIC MACULAR EDEMA (RHINE) | 2023-05-31 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-005118-74 | A PHASE II, MULTICENTER, RANDOMIZED STUDY TO COMPARE THE EFFICACY OF VENETOCLAX PLUS FULVESTRANT VERSUS FULVESTRANT IN WOMEN WITH ESTROGEN RECEPTOR−POSITIVE, HER2−NEGATIVE LOCALLY ADVANCED OR METASTAT... | 2021-05-05 | bad-data |
| Ongoing, reported early | 2018-000280-81 | A PHASE II, RANDOMIZED, BLINDED, PLACEBO-CONTROLLED STUDY OF MTIG7192A, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB IN CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-... | not-yet-due | |
| Reported results | 2018-000759-41 | A PHASE II TWO COHORT STUDY EVALUATING THE SAFETY AND EFFICACY OF COBIMETINIB PLUS ATEZOLIZUMAB IN BRAFV600 WILD-TYPE MELANOMA WITH CENTRAL NERVOUS SYSTEM METASTASES AND COBIMETINIB PLUS ATEZOLIZUMAB ... | 2023-04-13 | due-trials |
| Reported results | 2018-000780-91 | AN OPEN-LABEL, SINGLE-ARM PHASE IV STUDY TO ASSESS OCRELIZUMAB EFFICACY, SAFETY AND IMPACT ON PATIENT REPORTED OUTCOMES (PROS) IN PATIENTS WITH ACTIVE RELAPSING MULTIPLE SCLEROSIS (PRO-MSACTIVE) | 2021-02-15 | due-trials |
| Exempt, with results | 2018-001039-29 | A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED, CONTROLLED STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH CHOP OR CHP... | 2023-10-12 | not-yet-due |
| Exempt | 2018-001127-40 | A PHASE I/II TRIAL OF MOSUNETUZUMAB (BTCT4465A) AS CONSOLIDATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FOLLOWING FIRST-LINE IMMUNOCHEMOTHERAPY AND AS THERAPY IN PATIENTS WITH PREVIOUS... | not-yet-due | |
| Exempt | 2018-001141-13 | AN OPEN-LABEL, MULTICENTER, PHASE Ib/II TRIAL EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH POLATUZUMAB VEDOTIN IN PATIENTS WITH ... | not-yet-due | |
| Reported results | 2018-001416-30 | A PHASE III, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BALOXAVIR MARBOXIL IN COMBINATION WITH STANDARD-OF-CARE NEURAMINIDASE INHIBITOR IN HO... | 2020-04-16 | due-trials |
| Ongoing | 2018-001511-73 | A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-001881-40 | A phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of Atezolizumab or placebo in combination with neoadjuvant doxorubicin + cyclophosphamide f... | 2023-08-24 | bad-data |
| Ongoing, reported early | 2018-002087-12 | AN OPEN-LABEL STUDY OF RISDIPLAM IN INFANTS WITH GENETICALLY DIAGNOSED AND PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-002152-32 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (... | 2022-07-13 | bad-data |
| Reported results | 2018-002153-30 | A randomized, multicenter, open-label cross-over study to evaluate patient preference and satisfaction of subcutaneous administration of the fixed-dose combination of pertuzumab and trastuzumab in pat... | 2022-10-12 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-002154-70 | A MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF BALOXAVIR MARBOXIL IN OTHERWISE HEALTHY PEDIATRIC PATIENTS FROM BIRTH TO LESS THAN 1 YEAR WITH INFLU... | 2023-07-31 | bad-data |
| Reported results | 2018-002169-21 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE (OSELTAMIVIR)-CONTROLLED STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF BALOXAVIR MARBOXIL IN OTHERWISE HEALTHY PEDIATRIC PATIENTS 1 TO <... | 2019-08-27 | due-trials |
| Exempt, with results | 2018-002328-18 | A RANDOMIZED, MULTICENTER, PHASE Ib/III STUDY TO INVESTIGATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF ATEZOLIZUMAB SUBCUTANEOUS COMPARED WITH ATEZOLIZUMAB INTRAVENOUS IN PATIENTS WITH PREVIOUSLY ... | not-yet-due | |
| Completed, but no date, and reported results | 2018-002446-36 | AN OPEN LABEL PHASE 2A TRIAL ASSESSING THE CLINICAL EFFICACY AND SAFETY OF RO5459072 IN MODERATE TO SEVERE PSORIASIS | bad-data | |
| Reported results | 2018-002964-25 | A PHASE IB/II STUDY, EVALUATING THE SAFETY AND EFFICACY OF IDASANUTLIN IN COMBINATION WITH CYTARABINE AND DAUNORUBICIN IN PATIENTS NEWLY DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) AND THE SAFETY AND ... | 2020-09-10 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-002987-14 | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST HUN... | 2022-03-24 | bad-data |
| Reported results | 2018-003255-38 | A MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF GAZYVA SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA | 2023-01-25 | due-trials |
| Ongoing | 2018-003352-20 | An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B) | not-yet-due | |
| Ongoing, reported early | 2018-003398-87 | A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF MTAU9937A IN PATIENTS WITH MODERATE ALZHEIMER’S DISEASE ESTUDIO EN FASE II, MULT... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2018-003727-10 | A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE SAFETY AND EFFICACY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB PLUS GEMCITABINE PLUS OXALIPLATIN (R-GEMOX) VERSUS R-GEMO... | 2023-08-22 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-003898-94 | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH HUNTINGTON’S DISEASE | 2022-03-30 | bad-data |
| Reported results | 2018-004042-42 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (... | 2023-09-11 | due-trials |
| Listed as ongoing, but also has a completion date | 2018-004056-37 | A PHASE IIIB, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL EFFICACY STUDY OF BALOXAVIR MARBOXIL FOR THE REDUCTION OF DIRECT TRANSMISSION OF INFLUENZA FROM OTHERWISE HEALTHY PATI... | 2024-05-10 | bad-data |
| Listed as ongoing, but also has a completion date | 2018-004579-11 | A PHASE I/II, MULTICENTER, OPEN-LABEL, MULTI-ARM STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF IDASANUTLIN IN COMBINATION WITH EITHER CHEMOTHERAPY OR VENETO... | 2024-05-06 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2019-000810-12 | A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTA... | 2023-02-28 | bad-data |
| Exempt, with results Terminated | 2019-000989-38 | A PHASE Ib, MULTICENTER, OPEN-LABEL, 6-WEEK STUDY WITH A 48 WEEK EXTENSION TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF BALOVAPTAN IN CHILDREN AGES 2-4 YEARS WITH AUTISM SPECTRUM D... | 2020-05-06 | not-yet-due |
| Exempt, with results | 2019-001072-11 | A PHASE IB/III STUDY OF IPATASERTIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN HORMONE RECEPTOR POSITIVE AND HER2 NEGATIVE LOCALLY ADVANCED UNRESECTABLE OR MET... | not-yet-due | |
| Reported results | 2019-001139-30 | A SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY STUDY OF RO7049389 IN: (1) SINGLE- (WITH OR WITHOUT FOOD) AND MULTIPLE- (WITH MIDAZOLAM) ASCENDING DOSES IN HEALTHY VOLUNTEERS; (2) PATIENTS CHRO... | 2022-03-16 | due-trials |
| Reported results | 2019-001146-17 | A PHASE IIIB, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) IN COMBINATION WITH CARBOPLATIN PLUS ETOPOSIDE TO INVESTIGATE SAFETY AND EFFICACY IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMA... | 2023-07-13 | due-trials |
| Other | 2019-001155-39 | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB (RXDX-101) IN PEDIATRICS AND YOUNG ADULTS WITH NO CURATIVE FIRST-LINE TREATMENT OPTION OR RECURRENT/REFRACTORY SOLID TUMORS ... | not-yet-due | |
| Completed, but no date, and reported results Terminated | 2019-001453-10 | A MULTICENTER, LOW-INTERVENTIONAL STUDY DOCUMENTING THE EFFICACY, HEALTH-RELATED QUALITY OF LIFE, AND SAFETY OF STANDARD-OF-CARE TREATMENT WITH ECULIZUMAB OR TREATMENT WITH RAVULIZUMAB IN PATIENTS WIT... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2019-002067-10 | A randomized, double-masked, 48-week parallel-group, placebo-controlled, proof-of-concept study to investigate the efficacy and safety of RG7774 in patients with Diabetes Mellitus Type 1 or Type 2 wit... | 2023-07-19 | bad-data |
| Listed as ongoing, but also has a completion date | 2019-002086-35 | A PHASE II, RANDOMISED, ADAPTIVE, OPEN-LABEL PLATFORM TRIAL TO EVALUATE EFFICACY AND SAFETY OF MULTIPLE COMBINATION THERAPIES IN PARTICIPANTS WITH CHRONIC HEPATITIS B | 2024-07-19 | bad-data |
| Ongoing | 2019-002179-32 | A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB IN PATIENTS WITH MILD OR MODERATE HEMOPHILIA A WITHOUT FVIII INHIBITORS | not-yet-due | |
| Ongoing | 2019-002455-42 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIE... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2019-002463-10 | A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR FIRST-LINE TREATMENT OF RET FUSION-POSITIVE, METASTATIC NON-SMALL CELL LUNG CANCER | 2024-01-23 | bad-data |
| Ongoing | 2019-002488-91 | AN OPEN-LABEL, PHASE IIIB, SINGLE ARM, MULTICENTER SAFETY STUDY OF ATEZOLIZUMAB (TECENTRIQ) PLUS NABPACLITAXEL OR PACLITAXEL IN THE TREATMENT OF UNRESECTABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGA... | not-yet-due | |
| Other | 2019-002491-14 | A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA A... | not-yet-due | |
| Completed, but no date, and reported results | 2019-002784-10 | A PHASE IIIb, SINGLE ARM STUDY OF CARBOPLATIN OR CISPLATIN PLUS ETOPOSIDE WITH ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER ESTUDIO FASE IIIb... | bad-data | |
| Ongoing | 2019-002925-31 | A PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN PAT... | not-yet-due | |
| Ongoing | 2019-003301-97 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-ST... | not-yet-due | |
| Other | 2019-003327-37 | A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF VENETOCLAX AND OBINUTUZUMAB VERSUS FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITU... | not-yet-due | |
| Completed, but no date | 2019-003524-20 | A phase II multicenter, randomized, double-blind, 12-week treatment, 3-arm, parallel-group, placebo-controlled study to investigate the efficacy, safety and tolerability of RO7017773 in participants a... | bad-data | |
| Exempt | 2019-003787-48 | AN OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7248824 IN PARTICIPANTS WITH ANGELMAN SYNDROME | not-yet-due | |
| Other | 2019-003859-11 | RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE III STUDY OF ENTRECTINIB VERSUS CRIZOTINIB IN PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER HARBORING ROS1 GENE REARRANGEMENTS WITH ... | not-yet-due | |
| Other | 2019-003919-53 | A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH OCRELIZUMAB IN ADULT PATIENTS WITH PRIMARY PROGR... | not-yet-due | |
| Other | 2019-004034-42 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH ISN/RPS 2003 CLASS III OR IV LUPUS NEPHRITIS | not-yet-due | |
| Other | 2019-004092-39 | A PHASE III, MULTICENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE PHARMACOKINETICS, EFFICACY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PEDIATRIC PATIENTS WITH AQP4 ANTIBODY POS... | not-yet-due | |
| Exempt, with results Terminated | 2019-004200-35 | A PHASE Ib/II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF VENETOCLAX IN COMBINATION WITH TRASTUZUMAB EMTANSI... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-004431-23 | AN OPEN-LABEL, MULTI-CENTER, ROLL-OVER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF LONG-TERM ADMINISTRATION OF GANTENERUMAB IN PARTICIPANTS WITH ALZHEIMER’S DISEASE | 2023-01-04 | bad-data |
| Completed, but no date | 2019-004652-11 | RANDOMIZED, OPEN-LABEL PHASE 3B STUDY OF ETROLIZUMAB BASED INDUCTION THERAPY COMBINATIONS FOLLOWED BY ETROLIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS Randomiz... | bad-data | |
| Other | 2019-004773-29 | A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PR... | not-yet-due | |
| Other | 2019-004857-10 | A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING M... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2019-004895-21 | A PHASE II, SAFETY, AND EFFICACY STUDY OF TIRAGOLUMAB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY IN PATIENTS WITH METASTATIC AND/OR RECURRENT PD-L1-POSITIVE CERVICAL CANCER. STUDIO DI FASE II V... | 2023-09-18 | bad-data |
| Ongoing | 2019-004931-21 | A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB VERSUS ECULIZUMAB IN ADULT AND ADOLESCENT PATIENTS WITH PAROXYSMAL NOCTURNAL... | not-yet-due | |
| Ongoing, reported early | 2020-000100-11 | A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS DOCETAXEL MONO... | not-yet-due | |
| Other | 2020-000119-66 | A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB I... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2020-000402-29 | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2023-10-11 | bad-data |
| Reported results | 2020-000440-63 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN... | 2023-06-12 | due-trials |
| Completed, reported early | 2020-000441-13 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL OR ... | 2024-01-31 | not-yet-due |
| Ongoing | 2020-000502-29 | A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE,... | not-yet-due | |
| Ongoing | 2020-000597-26 | A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF CROVALIMAB VERSUS ECULIZUMAB IN ADULT AND ADOLESCENT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMO... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2020-000766-42 | AN OPEN-LABEL, MULTICENTER, ROLLOVER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF LONG-TERM GANTENERUMAB ADMINISTRATION IN PARTICIPANTS WITH ALZHEIMER'S DISEASE | 2023-03-06 | bad-data |
| Reported results | 2020-000791-38 | A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS | 2023-02-10 | due-trials |
| Other | 2020-000893-69 | A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS | not-yet-due | |
| Other | 2020-000894-26 | A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE S... | not-yet-due | |
| Reported results | 2020-001007-16 | A RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM, PHASE II, NEOADJUVANT STUDY EVALUATING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF GDC-9545 PLUS PALBOCICLIB COMPARED WITH ANASTROZOLE PLUS PALBOCICLI... | 2021-11-24 | due-trials |
| Other | 2020-001021-31 | A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF GLOFITAMAB IN COMBINATION WITH GEMCITABINE PLUS OXALIPLATIN VERSUS RITUXIMAB IN COMBINATION WITH GEMCITABIN... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2020-001154-22 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA. | 2020-07-28 | bad-data |
| Other | 2020-001168-28 | A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING M... | not-yet-due | |
| Reported results | 2020-001174-30 | AN EXPLORATORY, PROSPECTIVE, MULTI-CENTER, OPEN-LABEL, SINGLE-ARM, INTERVENTIONAL, PHASE IIB STUDY TO INVESTIGATE AQUEOUS HUMOR AND MULTIMODAL IMAGING BIOMARKERS IN TREATMENT-NAÏVE PATIENTS WITH DIABE... | 2022-12-22 | due-trials |
| Ongoing | 2020-001178-31 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE... | not-yet-due | |
| Other | 2020-001313-20 | A PHASE IIIb, GLOBAL, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF A 36-WEEK REFILL REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN P... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2020-001384-87 | A PHASE II, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE PHARMACODYNAMIC EFFECTS OF ONCE WEEKLY ADMINISTRATION OF GANTENERUMAB IN PARTICIPANTS WITH EARLY (PRODOMAL TO MILD) ALZHEIMER'S DI... | 2023-03-15 | bad-data |
| Reported results | 2020-001429-30 | A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) | 2023-02-10 | due-trials |
| Other | 2020-001733-12 | A PHASE IIIb, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SUBCUTANEOUS EMICIZUMAB IN PATIENTS FROM BIRTH TO 12 MONTHS OF AGE W... | not-yet-due | |
| Exempt | 2020-001743-10 | A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATINGTHE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH ADVANCED LIVER CANCERS (MORP... | not-yet-due | |
| Other | 2020-001847-16 | TUMOR-AGNOSTIC PRECISION IMMUNOONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL | not-yet-due | |
| Completed, report not yet due | 2020-001973-66 | A PHASE IIIB, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) IN COMBINATION WITH BEVACIZUMAB TO INVESTIGATE SAFETY AND EFFICACY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA NOT PR... | 2024-08-13 | not-yet-due |
| Ongoing | 2020-001984-10 | A PHASE II, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMPARED WITH PHYSICIAN'S CHOICE OF ENDOCRINE MONOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED ESTRO... | not-yet-due | |
| Reported results | 2020-002275-34 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF REMDESIVIR PLUS TOCILIZUMAB COMPARED WITH REMDESIVIR PLUS PLACEBO IN HOSPITALIZED PATIENTS WITH SEVERE C... | 2021-03-08 | due-trials |
| Other | 2020-002437-15 | A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) | not-yet-due | |
| Other | 2020-002475-35 | A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN ADULT AND ADOLESCENT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROM... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2020-002818-41 | A RANDOMIZED, MULTICENTER, DOUBLEBLIND, PLACEBO-CONTROLLED PHASE III STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR PLACEBO IN PATIENTS WITH HER2-POSITIV... | 2024-06-19 | bad-data |
| Ongoing | 2020-002851-39 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN VERSUS PEMBROLIZUMAB PLUS PEMETREXED AND CARBOP... | not-yet-due | |
| Ongoing | 2020-002852-19 | A PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB PLUS TIRAGOLUMAB AND ATEZOLIZUMAB PLUS PLACEBO AS FIRST-LINE TREATMENT IN PATIENTS WITH RECURRENT/METASTATIC PD-L1 POSITIVE SQUAMOUS CELL CAR... | not-yet-due | |
| Ongoing | 2020-002853-11 | A PHASE II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF NEOADJUVANT AND ADJUVANT TIRAGOLUMAB PLUS ATEZOLIZUMAB, WITH OR WITHOUT PLATINUM-BASED CHEMOTHERAPY, IN PATIENTS WITH PR... | not-yet-due | |
| Trial is outside EEC, and reported results | 2020-003173-22 | A Phase II Multi-Center, Randomized, Double-Blind, 24-Week, Parallel Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Children and Adolescents Age 5-... | bad-data | |
| Other | 2020-003233-38 | A PHASE III, RANDOMIZED, OPEN-LABEL ACTIVE COMPARATOR-CONTROLLED MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH PRIMARY MEMBRANOUS NEPHROPATHY | not-yet-due | |
| Completed, report not yet due | 2020-003256-32 | AN INTERVENTIONAL OPEN-LABEL MULTICENTER PHASE IV STUDY TO EVALUATE THE IMPACT OF EMICIZUMAB ON HEALTH-RELATED QUALITY OF LIFE, PHYSICAL ACTIVITY, AND JOINT HEALTH IN PATIENTS WITH SEVERE HEMOPHILIA A... | 2024-07-08 | not-yet-due |
| Listed as ongoing, but also has a completion date | 2020-003413-35 | A MULTICENTER, SINGLE ARM, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SATRALIZUMAB IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) | 2024-05-28 | bad-data |
| Not reported | 2020-003515-10 | A LONGITUDINAL, BIOMARKER STUDY OF ANTI-VEGF, TO EXPLORE THE RELATIONSHIP BETWEEN AQUEOUS HUMOR COMPOSITION AND MULTIMODAL RETINAL IMAGING IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND DIABETIC ... | 2022-12-19 | due-trials |
| Other | 2020-003681-40 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANC... | not-yet-due | |
| Reported results | 2020-003759-14 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT BEVACIZUMAB IN COMBINATION WITH CISPLATIN PLUS GEMCITABINE IN PATIENTS WITH UNTREATED, ADVANCED BILIARY T... | 2023-08-25 | due-trials |
| Reported results | 2020-003990-23 | A DOUBLE-BLIND, RANDOMIZED,PARALLEL-GROUP, PHASE 2 STUDY TO INVESTIGATE THE EFFECT OF RO7049665 ON THE TIME TO RELAPSE FOLLOWING STEROID TAPERING IN PATIENTS WITH AUTOIMMUNE HEPATITIS | 2021-11-18 | due-trials |
| Other | 2020-004128-41 | A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICACY OF OCRELIZUMAB IN COMPARISON WITH FINGOLIMOD IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTING ... | not-yet-due | |
| Exempt | 2020-004239-25 | A PHASE I/II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF ALECTINIB IN PEDIATRIC PARTICIPANTS WITH ALK FUSION POSITIVE SOLID OR CNS TUMORS FOR WHOM PRIOR TRE... | not-yet-due | |
| Ongoing | 2020-004241-36 | TIME AND MOTION STUDY OF A SUBCUTANEOUS FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR THE TREATMENT OF PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER. ESTUDIO CLINICO DE DETERMINACION D... | not-yet-due | |
| Other | 2020-004418-36 | A PHASE III, DOUBLE-BLIND, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) VERSUS PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE BLADDER CANCER WHO ARE CTDN... | not-yet-due | |
| Other | 2020-004427-16 | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2020-004436-21 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH GENERALIZED MYASTHENI... | 2024-09-02 | bad-data |
| Listed as ongoing, but also has a completion date | 2020-004523-16 | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION MULTICENTRIKUS, NYÍLT, KITERJE... | 2024-09-03 | bad-data |
| Ongoing | 2020-004606-60 | A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS WITH... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2020-004752-16 | PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF RO6889450 (RALMITARONT) IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AND NEGATIVE SYMPTOMS | 2023-05-08 | bad-data |
| Other | 2020-004839-25 | A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN S... | not-yet-due | |
| Exempt | 2020-004840-27 | A PHASE IB RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO-OCCLUSIVE EPISODES ... | not-yet-due | |
| Ongoing | 2020-004936-72 | A PHASE II, OPEN-LABEL, MULTICENTER, PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF BIOMARKER-DRIVEN THERAPIES IN PATIENTS WITH PERSISTENT OR RECURRENT RARE EPITHELIAL OVARIAN TUMORS | not-yet-due | |
| Other | 2020-004997-23 | A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE | not-yet-due | |
| Ongoing | 2020-005092-13 | A MULTICENTER, OPEN-LABEL PHASE IV STUDY TO EVALUATE OVERALL HEALTH, PHYSICAL ACTIVITY, AND JOINT OUTCOMES, IN PARTICIPANTS AGED = 13 AND < 70 YEARS WITH SEVERE OR MODERATE HEMOPHILIA A WITHOUT FVIII ... | not-yet-due | |
| Other | 2020-005231-78 | A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS LENVATINIB OR SORAFENIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZ... | not-yet-due | |
| Ongoing | 2020-005239-53 | PHASE III RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE IN PATI... | not-yet-due | |
| Reported results | 2020-005269-15 | A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR TREATMENT OF RET-MUTATED MEDULLARY THYROID CANCER | 2023-06-30 | due-trials |
| Reported results | 2020-005366-34 | A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, PHARMACOKINETICS, AND EFFICACY OF RO7496998 (AT-527) IN NON-HOSPITALIZED ADULT PATIENTS WITH ... | 2021-10-13 | due-trials |
| Other | 2020-005448-48 | A PHASE III, NON-INFERIORITY, RANDOMIZED, OPEN-LABEL, PARALLEL GROUP, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND RADIOLOGICAL AND CLINICAL EFFECTS OF SUBCUTANE... | not-yet-due | |
| Reported results | 2020-005759-18 | A MULTICENTER, PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OUTPATIENT STUDY TO EVALUATE THE EFFICACY, SAFETY, AND ANTIVIRAL ACTIVITY OF RO7496998 (AT-527) IN PATIENTS WITH MILD OR MODERATE... | 2021-12-07 | due-trials |
| Other | 2020-005760-57 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | not-yet-due | |
| Other | 2021-000062-14 | A PHASE IV MULTICENTER, OPEN-LABEL STUDY EVALUATING B CELL LEVELS IN INFANTS POTENTIALLY EXPOSED TO OCRELIZUMAB DURING PREGNANCY – THE MINORE STUDY | not-yet-due | |
| Ongoing | 2021-000063-79 | A PHASE IV MULTICENTER, OPEN-LABEL STUDY EVALUATING B CELL LEVELS IN INFANTS OF LACTATING WOMEN WITH CIS OR MS RECEIVING OCRELIZUMAB – THE SOPRANINO STUDY | not-yet-due | |
| Other | 2021-000097-29 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF OBINUTUZUMAB IN ADOLESCENT PATIENTS WITH ACTIVE CLASS III OR IV LU... | not-yet-due | |
| Other | 2021-000129-28 | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH E... | not-yet-due | |
| Reported results | 2021-000627-12 | A MULTICENTER, OBSERVATIONAL, 6 MONTH FOLLOW-UP STUDY OF PATIENTS WITH COVID 19 PREVIOUSLY ENROLLED IN A RO7496998 (AT-527) STUDY | 2022-03-16 | due-trials |
| Exempt, with results | 2021-001060-23 | A PHASE Ib/II OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF MOSUNETUZUMAB IN COMBINATION WITH TIRAGOLUMAB WITH OR WITHOUT ATEZOLIZUMAB IN PATIENTS WITH RELAPSE... | 2023-10-16 | not-yet-due |
| Completed, but no date | 2021-001088-26 | SAKURABONSAI: CLINICAL, IMAGING AND BIOMARKER OPEN-LABEL STUDY IN NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) WITH SATRALIZUMAB AS AN INTERVENTION | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2021-001184-25 | A PHASE III, MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GANTENERUMAB IN PARTICIPANTS AT RISK FOR OR AT THE EARLIEST STAGES O... | 2023-03-10 | bad-data |
| Other | 2021-001415-90 | INTERVENTIONAL PLATFORM STUDY INVESTIGATING THE IMPACT OF DIGITAL HEALTH SOLUTIONS ON HEALTH OUTCOMES AND HEALTH-CARE RESOURCE UTILIZATION IN PARTICIPANTS RECEIVING SYSTEMIC TREATMENT IN CLINICAL PRAC... | not-yet-due | |
| Other | 2021-001647-28 | A PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF GLOFITAMAB IN COMBINATION WITH RITUXIMAB (R) PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (CHOP) IN CIRCULATING TUMOR (ct)DNA ... | not-yet-due | |
| Other | 2021-001930-20 | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF LURBINECTEDIN IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH ATEZOLIZUMAB AS MAINTENANCE THERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL-CE... | not-yet-due | |
| Reported results | 2021-002076-39 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BALOVAPTAN IN PATIENTS WITH ACUTE ISCHEMIC STROKE AT HIGH RISK OF DEVELOPING MALIGNAN... | 2022-11-17 | due-trials |
| Exempt | 2021-002147-29 | A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TREATMENT COMBINATIONS IN PATIENTS WITH MELANOMA | 2024-05-28 | not-yet-due |
| Other | 2021-002346-33 | A PHASE IIIB, MULTINATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE PATIENT PREFERENCE FOR HOME ADMINISTRATION OF FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS A... | not-yet-due | |
| Reported results | 2021-002352-36 | A PHASE II, OPEN-LABEL, SINGLE-ARM DECENTRALIZED HOME-BASED APPROACH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALECTINIB IN LOCALLY ADVANCED OR METASTATIC ALK-POSITIVE SOLID TUMORS | 2022-05-17 | due-trials |
| Other | 2021-002395-39 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER BASKET STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH ANTI-N-MET... | not-yet-due | |
| Other | 2021-002695-40 | A PHASE II, SINGLE-ARM STUDY OF ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER PLATINUM-BASED CONCURRENT CHEMORADIATION... | not-yet-due | |
| Reported results Terminated | 2021-002968-49 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN PATIENTS WITH GUILLAIN-BARRÉ SYND... | 2022-11-04 | due-trials |
| Other | 2021-003192-34 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB AS MONOTHERAPY OR IN ADDITION TO B... | not-yet-due | |
| Completed, report not yet due | 2021-003226-71 | A PHASE IIIB, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED STUDY OF THE EFFECTIVENESS AND SAFETY OF A 36-WEEK REFILL REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB VS AFLIBERCEPT TREAT & EXT... | 2024-01-08 | not-yet-due |
| Ongoing | 2021-003296-33 | OPEN-LABEL MULTICENTER STUDY TO DETERMINE THE EFFECT OF OCRELIZUMAB ON LEPTOMENINGEAL INFLAMMATION IN MULTIPLE SCLEROSIS (LEGATO) | not-yet-due | |
| Other | 2021-003417-19 | A TWO-PART, SEAMLESS, MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7204239 IN COMBINAT... | not-yet-due | |
| Ongoing | 2021-003756-16 | A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE MASKED, ACTIVE COMPARATORCONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 ADMINISTERE... | not-yet-due | |
| Other | 2021-003772-14 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE EFFICACY OF FENEBRUTINIB IN RELAPSING MULTIPLE SCLEROSIS | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2021-003791-13 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACODYNAMICS OF 52 WEEKS OF TREATMENT WITH BASMISANIL IN CHILDREN WITH DUP15Q S... | 2024-03-04 | bad-data |
| Ongoing | 2021-004067-28 | A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PARTICIPANT AND HEALTHCARE PROFESSIONAL REPORTED PREFERENCE FOR SUBCUTANEOUS ATEZOLIZUMAB COMPARED WITH INTRAVENOUS ATEZOLIZUMAB FORM... | not-yet-due | |
| Other | 2021-004149-19 | A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III ... | not-yet-due | |
| Completed, but no date | 2021-004390-31 | A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE MASKED, ACTIVE COMPARATORCONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 IN COMBINAT... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2021-005332-27 | A PHASE Ib, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB IN PEDIATRIC PATIENTS HOSPITALIZED WITH COVID-19 | 2024-03-27 | bad-data |
| Exempt | 2021-005712-62 | A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF TH... | 2024-08-15 | not-yet-due |
| Ongoing | 2021-005746-15 | A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis | not-yet-due | |
| Other | 2021-006255-34 | A PHASE II, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE PHARMACODYNAMICS, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF RO7204239 IN PARTICIPANTS WITH FAC... | not-yet-due | |
| Other | 2021-006326-48 | A PHASE I/II, OPEN-LABEL, SINGLE-ARM, TWO-PART TRIAL TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF GLOFITAMAB IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN PEDIATRIC AND Y... | not-yet-due | |
| Other | 2021-006430-39 | A RANDOMIZED OPEN LABEL PHASE II STUDY OF IMMUNE CHECKPOINT INHIBITOR COMBINATIONS WITH AXITINIB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC RENAL CELL CARCINOMA ... | not-yet-due | |
| Exempt | 2021-006816-10 | A PHASE I/II, OPEN-LABEL, MULTI-COHORT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CEVOSTAMAB IN PRIOR B CELL MATURATION ANTIGEN-EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA | not-yet-due | |
| Other | 2022-000369-42 | A PHASE III, INTERNATIONAL, MULTICENTER, RANDOMISED OPEN LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB VERSUS MMF IN PATIENTS WITH CHILDHOOD ONSET IDIOPATHIC NEPHROTIC SYNDROME | not-yet-due | |
| Other | 2022-000631-23 | A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II STUDY OF MULTIPLE DOSES OF RO7247669 IN PARTICIPANTS WITH PREVIOUSLY UNTREATED UNRESECTABLE OR METASTATIC MELANOMA | not-yet-due | |
| Other | 2022-000691-19 | A two-part, open-label systemic gene delivery study to evaluate the safety and expression of RO7494222 (SRP-9001) in subjects under the age of four with Duchenne muscular dystrophy | not-yet-due | |
| Other | 2022-001157-23 | A PHASE II, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF THE INTRAVENOUS FIXED-DOSE COMBINATION (IV FDC) OF TIRAGOLUMAB AND ATEZOLIZUMAB IN PARTICIPANTS WITH LOCALLY ADVA... | not-yet-due | |
| Other | 2022-001440-18 | A PHASE II, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, CONTROLLED STUDY OF RO7247669 PLUS PLATINUM-BASED CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTR... | not-yet-due | |
| Other | 2022-001991-32 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, BIOMARKERS, AND EFFICACY OF TOMINERSEN IN INDIVIDUALS WITH PRODROMAL AND EARLY MANIFEST HUNTINGTON’... | not-yet-due | |
| Other | 2022-002265-15 | A PHASE II, RANDOMIZED, MULTICENTER, OPEN LABEL, CONTROLLED STUDY OF RO7247669 ALONE OR IN COMBINATION WITH TIRAGOLUMAB VERSUS ATEZOLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR ME... | not-yet-due | |
| Ongoing | 2022-002443-21 | A PHASE II, SINGLE-ARM STUDY OF GIREDESTRANT IN PATIENTS WITH GRADE 1 ENDOMETRIAL CANCER STUDIO A BRACCIO SINGOLO DI FASE II SU GIREDESTRANT IN PAZIENTI CON CARCINOMA DELL’ENDOMETRIO DI GRADO 1 | not-yet-due | |
| Exempt | 2022-003048-28 | A PHASE Ib/II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, ACTIVITY, AND PHARMACOKINETICS OF DIVARASIB IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH PREVIOUSLY UNTREATED AD... | not-yet-due | |
| Other | 2022-003414-36 | AN OPEN LABEL, MULTICENTER EXTENSION STUDY FOR PATIENTS PREVIOSULY ENROLLED IN A GENENTECH AND/OR F. HOFFMAN-LA ROCHE SPONSORED STUDY | not-yet-due | |
| Ongoing | 2022-003708-33 | A PHASE II, OPEN LABEL, RANDOMIZED, NON-COMPARATIVE COHORTS STUDY OF ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB PLUS TIRAGOLUMAB IN SOLID TUMORS WITH RESECTABLE DISEASE WITH INTERMEDIATE-HIGH RISK OF RECUR... | not-yet-due |